Page 11234..1020..»

Archive for the ‘Genetic Testing’ Category

Should I get a prenatal genetic screening test and what can I expect? – Monitor

By: Cristela Hernandez, MD Maternal-Fetal Medicine

Pregnant women commonly ask their doctor, Will my baby be healthy? While the vast majority of babies are born healthy, all pregnancies are at risk for birth defects and genetic diseases. Two to three percent of babies are born with birth defects and 1 in 150 live births involve a chromosomal abnormality. Prenatal care involves screening for chromosomal abnormalities, genetic syndromes, and birth defects. Genetic screening is offered to all women during the first or second trimester of pregnancy. Subsequently, the doctor will review the mothers results to determine, with as much accuracy as possible, whether a specific birth defect or genetic condition is present in her baby. Certain conditions can increase the mothers risk, such as maternal age over 35, or a family history of birth defects and genetic disease. Keep in mind, that although many advances have been made, it is not possible to predict all birth defects or genetic disorders.

Prenatal genetic testing initially focused on the detection of Down Syndrome because it is the most common chromosomal abnormality, but testing has expanded to a broad range of other genetic disorders. Chromosomal abnormalities include extra or missing chromosomes such as Down Syndrome, which arises from an extra chromosome number 21. In addition, chromosomes can have abnormalities such as missing or duplicated fragments, or rearrangements from one chromosome to another. Other genetic disorders are caused by mutations in single genes, such as cystic fibrosis. Lastly, mutations in the mitochondrial DNA can also cause genetic disorders. The field of genetic disorders is complex and genetic counseling is very helpful when these abnormalities are encountered.

Prenatal genetic testing generally begins with a mothers blood test and a fetal ultrasound exam. It is considered a screening test and does not entail any risk to the pregnancy, but is not considered a final diagnosis. Diagnostic invasive testing includes chorionic villus sampling and amniocentesis, and these can provide a definitive diagnosis. Chorionic villous sampling may be performed in the first trimester and an amniocentesis in the second trimester. These procedures can rarely lead to a miscarriage, so benefits and risks should be carefully considered.

Birth defects can be identified with fetal ultrasound exams and newer technology now includes 3- dimensional imaging. If a birth defect is suspected, a detailed fetal ultrasound is recommended. A referral to a Maternal-Fetal Medicine specialist can be helpful to address the multiple issues involved.

All of this information, in response to a concerned mothers simple question, Will my baby be healthy? may seem overwhelming. It is important for every mother to discuss with her doctor the options in prenatal screening and her individual risk of having a genetic disease or birth defect. Prenatal genetic testing provides many benefits, including: reassuring parents when results are normal, identifying conditions which can be treated with fetal therapy before birth, and optimizing care for affected newborns. Such testing may prove very useful for the mother and doctors caring for her baby.

Read more from the original source:
Should I get a prenatal genetic screening test and what can I expect? - Monitor

Genetic Mutations Linked to Higher Breast Cancer Risk Are the Same for Black, White Women – Breastcancer.org

The genetic mutations that can increase breast cancer risk, including mutations in the BRCA1, BRCA2, and PALB2 genes, are the same for both black and white women, which means that currently available genetic tests are effective for black women, according to a study.

The research was published online on May 19, 2020, by the Journal of the National Cancer Institute. Read the abstract of Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.

A germline variant is a change, or mutation, in a gene that is inherited from your parents and is in all your DNA.

Three of the most well-known genes that can mutate and raise the risk of breast and/or ovarian cancer are BRCA1, BRCA2, and PALB2. Women who inherit a harmful mutation, or abnormal change, in any of these genes from their mothers or their fathers have a much higher-than-average risk of developing breast cancer and/or ovarian cancer. Men with these mutations have an increased risk of breast cancer, especially if the BRCA2 gene is affected, and possibly of prostate cancer. Many inherited cases of breast cancer have been associated with mutations in these three genes.

The function of the BRCA and PALB2 genes is to keep breast cells growing normally and prevent any cancer cell growth. But when these genes contain mutations that are passed from generation to generation, they do not function normally and breast cancer risk increases. Abnormal BRCA1, BRCA2, and PALB2 genes may account for up to 10% of all breast cancers, or 1 out of every 10 cases.

Earlier studies looking at the genetic mutations linked to a higher risk of breast cancer included mainly white women, so it has been unclear if the same genetic mutations increased breast cancer risk by the same amount in black women.

Earlier research studies looking at genetic mutations linked to breast cancer in black women were very small, so the researchers could only conclude that mutations in the BRCA1 and BRCA2 genes were linked to a higher risk of breast cancer in black women.

So the researchers who did this study were concerned that current genetic tests might not be looking for the correct mutations linked to a higher risk of breast cancer in black women.

The study included 5,054 black women who had been diagnosed with breast cancer and 4,993 black women of the same ages who had not been diagnosed with breast cancer.

All the women had genetic testing that looked for mutations in 23 genes known to be linked to a higher risk of cancer.

Harmful mutations were found in:

Mutations in the BRCA1, BRCA2, and PALB2 genes were linked to a high risk of breast cancer.

Mutations in the RAD51D gene were linked to a high risk of estrogen-receptor-negative breast cancer.

Mutations in the CHEK2, ATM, ERCC3, and FANCC genes were linked to a moderate risk of estrogen-receptor-positive breast cancer.

Mutations in the RECQL gene were linked to a moderate risk of all types of breast cancer.

"This means that the [genetic tests] that are currently available to test women diagnosed with breast cancer or women at high risk due to their family history will be useful for African American women," said lead author Julie Palmer, Karin Grunebaum Professor in Cancer Research at the Boston University School of Medicine.

If you are a black woman who has been diagnosed with breast cancer or who hasnt been diagnosed but you have a strong family history of the disease, this study offers reassurance that current genetic tests will accurately find any mutations linked to a higher risk of breast cancer.

Statistics show that rates of genetic testing are much lower in black women diagnosed with breast cancer than in white women diagnosed with breast cancer.

In February 2019, the American Society of Breast Surgeons issued updated guidelines saying that genetic testing should be made available to everyone who has been diagnosed with breast cancer.

There are a number of reasons why someone diagnosed with breast cancer or who is at high risk because of family history might want to consider genetic testing:

If youve been diagnosed with breast cancer or are at high risk because of family history, you may want to talk to your doctor or a licensed certified genetic counselor about your diagnosis and/or your family history and ask if having a genetic test makes sense for you. A licensed certified genetic counselor or your doctor can help you understand the test and accurately interpret the results.

For more information on genetic testing, including types of genetic tests and how results are reported, visit the Breastcancer.org Genetic Testing pages.

For more information on genes and genetic mutations linked to breast cancer, as well as all the risk-lowering steps you can take if you have a genetic mutation, visit the Breast Cancer Risk Factors: Genetics page in the Breastcancer.org Lower Your Risk section.

To discuss being at high risk for breast cancer with other people, join the Breastcancer.org Discussion Board forum High Risk for Breast Cancer. If you've tested positive for a mutation linked to breast cancer and would like to talk about this with others who have also tested positive, join the forum Positive Genetic Test Results.

Written by: Jamie DePolo, senior editor

Published on June 2, 2020 at 10:18 AM

More:
Genetic Mutations Linked to Higher Breast Cancer Risk Are the Same for Black, White Women - Breastcancer.org

The Global Preimplantation Genetic Testing Market is expected to grow from USD 418.13 Million in 2018 to USD 946.13 Million by the end of 2025 at a…

NEW YORK, June 5, 2020 /PRNewswire/ --The Global Preimplantation Genetic Testing Market is expected to grow from USD 418.13 Million in 2018 to USD 946.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.37%.

Read the full report: https://www.reportlinker.com/p05871267/?utm_source=PRN

The positioning of the Global Preimplantation Genetic Testing Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Preimplantation Genetic Testing Market including are ABBott Laboratories, Agilent Technologies, Inc., Oxford Gene Technology, Perkinelmer, Inc., Thermo Fisher Scientific Inc., Beijing Genomics Institute, Combimatrix Corporation, Emerson Electric Co., Invicta Genetics, and Progenesis.

On the basis of Technology, the Global Preimplantation Genetic Testing Market is studied across Comparative Genomic Hybridization, Fluorescence in Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction, and Single-Nucleotide Polymorphism.

On the basis of Offering, the Global Preimplantation Genetic Testing Market is studied across Instruments Services, Reagents and Consumables, and Software and Services.

On the basis of Procedure Type, the Global Preimplantation Genetic Testing Market is studied across Preimplantation Genetic Diagnosis Off-Line Procedure Type and Preimplantation Genetic Screening.

On the basis of Application , the Global Preimplantation Genetic Testing Market is studied across Aneuploidy, Gender Identification, HLA Typing, Single Gene Disorders, Structural Chromosomal Abnormalities, and X-Linked Disorders.

On the basis of End User , the Global Preimplantation Genetic Testing Market is studied across Contract Research and Manufacturing Organizations, Hospitals, Diagnostic Labs, and Service Providers, and Research Laboratories & Academic Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Preimplantation Genetic Testing Market2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Preimplantation Genetic Testing Market3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Preimplantation Genetic Testing Market4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Preimplantation Genetic Testing Market5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Preimplantation Genetic Testing Market

The report answers questions such as:1. What is the market size of Preimplantation Genetic Testing market in the Global?2. What are the factors that affect the growth in the Global Preimplantation Genetic Testing Market over the forecast period?3. What is the competitive position in the Global Preimplantation Genetic Testing Market?4. Which are the best product areas to be invested in over the forecast period in the Global Preimplantation Genetic Testing Market?5. What are the opportunities in the Global Preimplantation Genetic Testing Market?6. What are the modes of entering the Global Preimplantation Genetic Testing Market?

Read the full report: https://www.reportlinker.com/p05871267/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View post:
The Global Preimplantation Genetic Testing Market is expected to grow from USD 418.13 Million in 2018 to USD 946.13 Million by the end of 2025 at a...

Impact of Corona on Direct-Access Genetic Testing Market : What is the expected revenue for 2026? – Cole of Duty

The report attempts to offer high-quality and accurate analysis of the global Direct-Access Genetic Testing Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Direct-Access Genetic Testing market that are impacting their business. Readers can become aware of crucial opportunities available in the global Direct-Access Genetic Testing market as well as key factors driving and arresting market growth. The research study also provides deep geographical analysis of the global Direct-Access Genetic Testing market and sheds light on important applications and products that market players can focus on for achieving strong growth.

Major players profiled in the report:

23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull Genomes

To know How COVID-19 Pandemic Will Impact This Direct-Access Genetic Testing Market/Industry -Request sample copy of this report:https://www.reporthive.com/request_sample/2334146

You can thoroughly assess the strengths and weaknesses of your competitors using our competitive analysis. In the report, you also have access to comprehensive production and shipment analysis from point of origin to end user purchase. Furthermore, you are informed about latest industry developments to help you stay ahead of your competitors. Our analysts are always on their toes to continuously track and analyze any changes or developments in the Direct-Access Genetic Testing industry. The report is filled with statistical presentations, market figures related to revenue, volume, CAGR, and share, and global and regional market forecasts.

The report includes a detailed segmentation study of the global Direct-Access Genetic Testing market, where all of the segments are analyzed in terms of market growth, share, growth rate, and other vital factors. It also provides the attractiveness index of segments so that players can be informed about lucrative revenue pockets of the global Direct-Access Genetic Testing market. The extensive evaluation of segments provided in the report will help you to direct your investments, strategies, and teams to focus on the right areas of the global Direct-Access Genetic Testing market.

Segmentation by Type:

Help-Seeking ADReminder ADProduct Claim AD

Segmentation by Application:

OnlineOffline

For More Information or Query or Customization Before Buying, Visit at -:https://www.reporthive.com/request_customization/2334146

Key questions answered in this research study

Take a look at some of the important sections of the report

Market Overview:Readers are informed about the scope of the global Direct-Access Genetic Testing market and different products offered therein. The section also gives a glimpse of all of the segments studied in the report with their consumption and production growth rate comparisons. In addition, it provides statistics related to market size, revenue, and production.

Production Market Share by Region:Apart from the production share of regional markets analyzed in the report, readers are informed about their gross margin, price, revenue, and production growth rate here.

Company Profiles and Key Figures: In this section, the authors of the report include the company profiling of leading players operating in the global Direct-Access Genetic Testing market. There are various factors considered for assessing the players studied in the report: markets served, production sites, price, gross margin, revenue, production, product application, product specification, and product introduction.

Manufacturing Cost Analysis:Here, readers are provided with detailed manufacturing process analysis, industrial chain analysis, manufacturing cost structure analysis, and raw materials analysis. Under raw materials analysis, the report includes details about key suppliers of raw materials, price trend of raw materials, and important raw materials.

Market Dynamics:The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends in this section.

We follow industry-best practices and primary and secondary research methodologies to prepare our market research publications. Our analysts take references from company websites, government documents, press releases, and financial reports and conduct face-to-face or telephonic interviews with industry experts for collecting information and data. There is one complete section of the report dedicated for authors list, data sources, methodology/research approach, and publishers disclaimer. Then there is another section that includes research findings and conclusion.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

About Us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

The rest is here:
Impact of Corona on Direct-Access Genetic Testing Market : What is the expected revenue for 2026? - Cole of Duty

Illinois Man Kyle D. McLean Admits Role in $4.6 Million Health Care Fraud Related to Genetic Testing – STL.News

(STL.News) An Illinois man today admitted his role in a scheme to defraud the Medicare Program in connection with fraudulent orders for genetic tests, U.S. Attorney Craig Carpenito announced.

Kyle D. McLean, 36, of Arlington Heights, Illinois, pleaded guilty by videoconference before U.S. District Judge Brian R. Martinotti to a superseding information charging him with one count of conspiracy to defraud the United States in connection with a scheme to commit health care fraud. McLean and five co-defendants were previously charged by indictment in September 2019 in connection with the conspiracy and a related scheme.

According to documents filed in this case and statements made in court:

McLean and certain of his conspirators operated Privy Health Inc., a company that acquired DNA samples and Medicare information from hundreds of patients through various methods, including offering $75 gift cards to patients, all without the involvement of a treating health care professional. Privy partnered with another company, Ark Laboratory Network LLC, which purported to operate a network of laboratories that facilitated genetic testing. Matthew S. Ellis, a physician based in Gainesville, Florida, and a co-defendant charged in the indictment, served as the ordering physician who authorized genetic testing for hundreds of patients across the country that he never saw, examined, or treated. These included patients from New Jersey and various other states where Ellis was not licensed to practice medicine. Through this process, Ellis, McLean, and others submitted and caused to be submitted fraudulent orders for genetic tests to numerous clinical laboratories. These orders falsely certified that Ellis was the patients treating physician and, in some cases, falsely indicated that a patient had a personal or family history of cancer. In 2018 alone, Medicare paid clinical laboratories at least approximately $4.6 million for genetic tests that Ellis ordered as part of this scheme.

The charge to which McLean pleadedguilty carries a maximum penalty of five years in prison and a fine of $250,000, or twice the gross grain or loss from the offense. Sentencing is scheduled for Oct. 9, 2020.

A co-defendant, Kacey C. Plaisance, of Altamonte Springs, Florida, previously pleaded guilty and is scheduled to be sentenced on September 17, 2020.

U.S. Attorney Carpenito credited the U.S. Department of Health and Human Services, Office of Inspector General, under the direction of Special Agent in Charge Scott Lampert; and special agents of the U.S. Attorneys Office for the District of New Jersey with the investigation leading to todays guilty plea.

The government is represented by Senior Trial Counsel Bernard J. Cooney of the Health Care Fraud Unit of the U.S. Attorneys Office in Newark.

The charge and allegations against the remaining defendants are merely accusations, and they are presumed innocent unless and until proven guilty.

CLICK to VIEW SOURCE

Follow this link:
Illinois Man Kyle D. McLean Admits Role in $4.6 Million Health Care Fraud Related to Genetic Testing - STL.News

Mining company blasts through 46000-year-old cultural site in Australia – The Architect’s Newspaper

Multinational iron ore mining company Rio Tinto is under fire for blasting through a 46,000-year-old Aboriginal cultural site in Western Australia last monthespecially since the company reportedly knew about the cave dwellings significance as far back as 2014.

On May 24, Rio Tinto, in trying to expand their Brockman 4 iron ore mine in the Pilbara region, destroyed two cave systems, Juukan 1 and 2, that showed evidence of continual human habitation dating back 46,000 years. The sites owners, the indigenous Puutu Kunti Kurrama and Pinikura (PKKP) peoples, reportedly only learned of the demolition on May 15; it was allowed to move ahead as an agreement had already been signed in 2013, one year before an archeological survey to the area was conducted.

What did that survey find? Archeologists reportedly recovered over 7,000 high-quality artifacts, including tools, grinding stones, and 4,000-year-old pleated hair braids that genetic testing linked to still-living Aboriginal peoples. Still, despite the discovery that the Juukan Gorge dwellings were more culturally, historically, and scientifically important than first thought, the demolition was still allowed to proceed under the Aboriginal Heritage Act. In 2013, Rio Tinto secured a permit based on the premise that the caves were of low historic value, and following the provisions set out by the act, were thus free from legal culpability for excavating, destroying, damaging, concealing or in any way altering any Aboriginal site.

Rio Tinto also remains in possession of the items recovered in 2014, and in 2016, even put out a documentary laying out PKKP concerns over the areas preservation, somewhat undermining the companys claim that this was unavoidable. The results of the final archeological report were never made public until summaries were recently provided to the press.

The chief executive of Rio Tinto iron ore, Chris Salisbury, apologized in an interview with Radio National this morning, calling it a misunderstanding, but as ABC News pointed out, the company knew the caves likely had archeological significance as far back as December of 2008.

For their part, the PKKP reportedly tried to stop the destruction but were told by Rio Tinto that the explosives had already been laid and that it was too late.

Read more from the original source:
Mining company blasts through 46000-year-old cultural site in Australia - The Architect's Newspaper

Studies of Brain Activity Aren’t as Useful as Scientists Thought – Duke Today

Hundreds of published studies over the last decade have claimed it's possible to predict an individuals patterns of thoughts and feelings by scanning their brain in an MRI machine as they perform some mental tasks.

But a new analysis by some of the researchers who have done the most work in this area finds that those measurements are highly suspect when it comes to drawing conclusions about any individual persons brain.

Watching the brain through a functional MRI machine (fMRI) is still great for finding the general brain structures involved in a given task across a group of people, said Ahmad Hariri, a professor of psychology and neuroscience at Duke University who led the reanalysis.

Scanning 50 people is going to accurately reveal what parts of the brain, on average, are more active during a mental task, like counting or remembering names, Hariri said

Functional MRI measures blood flow as a proxy for brain activity. It shows where blood is being sent in the brain, presumably because neurons in that area are more active during a mental task.

The problem is that the level of activity for any given person probably wont be the same twice, and a measure that changes every time it is collected cannot be applied to predict anyones future mental health or behavior.

Hariri and his colleagues reexamined 56 published papers based on fMRI data to gauge their reliability across 90 experiments. Hariri said the researchers recognized that the correlation between one scan and a second is not even fair, its poor.

They also examined data from the brain-scanning Human Connectome Project -- Our fields Bible at the moment, Hariri called it -- and looked at test/retest results for 45 individuals. For six out of seven measures of brain function, the correlation between tests taken about four months apart with the same person was weak. The seventh measure studied, language processing, was only a fair correlation, not good or excellent.

Finally they looked at data they collected through the Dunedin Multidisciplinary Health and Development Study in New Zealand, in which 20 individuals were put through task-based fMRI twice, two or three months apart. Again, they found poor correlation from one test to the next in an individual.

The bottom line is that task-based fMRI in its current form cant tell you what an individuals brain activation will look like from one test to the next, Hariri said. The new analysis, appears June 3 in Psychological Science

This is more relevant to my work than just about anyone elses! Hariri said, his voice rising. This is my fault. Im going to throw myself under the bus. This whole sub-branch of fMRI could go extinct if we cant address this critical limitation.

Hariri has been using fMRI data as part of a long-term study of 1,300 undergraduate Duke students. By combining brain scans, genetic testing and psychological assessments, Hariri is searching for biomarkers of individual differences in the way people process thoughts and emotions, such as why one person comes away from a traumatic event with PTSD or depression and another does not.

We cant continue with the same old hot spot research, Hariri said. We could scan the same 1,300 undergrads again and we wouldnt see the same patterns for each of them.

One possible solution to the reliability problem, using existing technology, would be to collect data for a full hour or longer in the scanner, not just five minutes. Hariri also said developing new tasks from the ground up with the explicit purpose of reliably measuring individual differences in brain activity is another strategy. In the meanwhile, Hariri and his team have shifted their focus to MRI measures of brain structure, which are highly reliable.

Its not as if we havent known these issues of reliability, but this paper brings them together more sharply, said Russell Poldrack, the Albert Ray Lang Professor of Psychology at Stanford University, who had a 15-year-old fMRI paper among those that were reanalyzed.

This is a good wakeup call, and its a marker of Ahmads integrity that hes taking this on, said Poldrack, who was not involved in the meta-analysis but said he has had suspicions about fMRI reliability for a few years now.

Connectivity mapping seeing how areas of the brain are connected to address a task more than just what areas are active is going to be the way forward, Poldrack predicted. Hariri agreed that identifying patterns of activity throughout the brain rather than in one or two areas may improve reliability.

In the meantime, the sociology behind a dramatic debunking of a scientific tool is going to be interesting to watch, Hariri and Poldrack both said.

Theres three things you can do, Poldrack said. You can just up and quit, you can stick your head in the sand (and act as if nothing has changed), or you can dig in and try to solve the problems.

This analysis was supported by the U.S. National Science Foundation. The Dunedin Study is supported by the U.S. National Institute on Aging (R01AG049789, R01AG032282) and the UK Medical Research Council (P005918), the New Zealand Health Research Council and the New Zealand Ministry of Business, Innovation and Employment (MBIE). The Human Connectome Project is supported by 16 centers of the U.S. National Institutes of Health via the Blueprint for Neuroscience Research.

CITATION: What is the Test-Retest Reliability of Common Task-fMRI Measure? New Empirical Evidence and a Meta-Analysis, Maxwell L. Elliott, Annchen R. Knodt, David Ireland, Meriwether L. Morris, Richie Poulton, Sandhya Ramrakha, Maria L. Sison, Terrie E. Moffitt, Avshalom Caspi, Ahmad R. Hariri. Psychological Science, June 3, 2020. DOI: 10.1177/0956797620916786

Read the original here:
Studies of Brain Activity Aren't as Useful as Scientists Thought - Duke Today

Genetic genealogy companies Ancestry, 23andMe begin COVID-19 research – Detroit Free Press

Ancestry and 23andMe offer direct-to-consumer DNA tests.(Photo: Reviewed.com/Jackson Ruckar)

It's a question that has vexed researchers from the beginning of the coronavirus outbreak: Why do some people get severely ill and die from COVID-19, while others have mild symptoms or none at all?

Now, scientists at two direct-to-consumer genealogy DNA companies hope to use the genomesthey've collected from millions of people over the years to see if they can find a genetic explanation toanswer that question.

Both 23andMe and Ancestry have launched COVID-19 studies, asking U.S. adult customers who've already submitted DNA samples to answer online questions about how the virus affected or didn't affect them.

"From the early days ... I think it was clear to all of us that some people were getting very, very sick when they were affected with coronavirus, and some people had hardly any symptoms at all," said Dr. Catherine Ball,chief scientific officer at Utah-based Ancestry."It turns out that there are plenty of people who have no symptoms. The spectrum of human response to the same pathogen is unusual.

"And even with a bunch of comorbidities and other problems, it's still remarkably divergent in different people, even if they have the same age and have the same overall health. And soto geneticists, that looks like there's a genetic factor in whether people become infected in the first placeor have serious or mild symptoms."

With 16 million people who've already spit in vials and sent them to Ancestryfor genetic testing to find blood relatives who might be closely or distantly related or learn how much of their DNA suggests their relatives came from Africa or Asia or were Native American or European, Ball said the companyknew it had a potentially useful data pool to tap for COVID-19 research.

"We clearly want to take the opportunity to unleash that power to be able to see if there are genetic signals, and be able to help researchers and people making drugs and therapeutics and vaccines dosmarter work faster," she said.

Dr. Catherine Ball, chief scientific officer for Utah-based Ancestry.(Photo: Ancestry)

Of those 16 million DNA customers through Ancestry, so far about 500,000people have already taken an online survey to participate in the company'scoronavirus research.

At 23andMe, principal scientist Adam Auton said the California-based company's COVID-19 genome-wide association study launched in April.

About 10 million of itsgenotype customers are eligible for the study, he said.Of them, about 80%have consented to participate in research, and600,000 customers have opted into the COVID-19 study.

"It is a really quite tremendous response to the study and I think shows that people really do want to try and contribute to help understand and fight this disease," said Auton.

Both Ancestry and 23andMeacknowledge that the bigger the sample size, the better their research will be.

"Never ask a scientisthow much data she needsbecause she always needs more," Ball said. "We're really hoping to get a minimum of a million respondentsbecause we need to have a decent number of people who have tested positive to give us a statistical signal."

So far, about9,000 people in 23andMe'sCOVID-19 study reported that theytested positive for coronavirus.

"That's a pretty substantial number," Auton said. "However, it's the nature of genetic studies that we really need very large numbers of people to be able to draw connections between the genetic information and people's health information."

A worker at 23andMe performs DNA testing on samples provided by customers.(Photo: 23andMe)

Since the pandemic began,about 1.6million people in the United States, a country of 330 million, have tested positive for COVID-19. As the virus continues to spread,and more people get coronavirus diagnoses, the companies suspect that the number of people who will go on to enroll in their studies also is likely to rise.

"We understand this is an evolving situation," Ball said. "And while we can't shelter in place forever, at some point, as we're opening up our cities and states, more people will start contracting the virus."

Anyone who may have already filled out anonline COVID-19 survey on Ancestry.com or 23andMe.com, saying they had not yet had the virus, can go back and revise their answers later to reflect that they've contracted it.

To expand its research of people who've had COVID-19 even more, Auton said 23andMeis now offering tomail a free DNA test kit to any U.S adult who was hospitalized with COVID-19, but has not yet submitted a DNA sample to the company.

"We are essentially asking if people have been hospitalized with COVID-19, and they have recovered, if they would like to participate inour research. They can come to our website and we'll offer them a free kit,"Auton said.

The contents of a 23andMe kit.(Photo: 23andMe)

"We're very much interested in trying to get the word out so that people to hear about this because really every data point is going to be pretty valuable."

23andMe has emailed customers in areas hardest hit so far in the pandemic including those in Michiganto let them know about its study, Auton said.

"The best thing that we can do to make a difference for COVID is to really publish the results that we find and make them available to the research and scientific communities," he said.

23andMe haspublishedmore than 150 studies in peer-reviewed scientific journals, "the majority of which come from collaboration with the broader academic and the scientific community," Auton said,since it launched in 2006with its direct-to-consumer DNA kit.

But the company ran afoul of the U.S. Food and Drug Administration in 2013, when the agency ordered 23andMeto halt the release of genetic health information to customers, saying the company had yet to prove its tests were"analytically or clinically validated."

After revamping, the company passed FDA muster in 2017, and got authorization tooffergenetic healthreports that outlinedrisk for 10conditions, including late-onset Alzheimers disease andParkinsons disease.

Ancestry is new to the health genetics business. It launched AncestryHealth in 2019, with the disclaimer that its tests are physician-ordered and not diagnostic, but offer "health insights" into whether a person might be a carrier for cystic fibrosis or sickle cell anemia or whether there's a genetic variant associated with a higher risk for breast cancer or colon cancer.

Ball said Ancestry also will seek to publish its COVID-19 research findings, too.

"We will be doing our very best to publish our findings as quickly as possible, and making them as useful to clinicians and other researchers as quickly as possible," she said.

Ancestry DNA(Photo: Melissa Rorech)

Both companies are looking for research partners for the coronavirus studies. Ancestry has had nibbles from universities, biotech and pharmaceutical companies, but Ball said, right now, the focus is on safeguarding the privacy of its customers.

"We typically do not share data out with third parties," Ball said. "That's an unusual activity for us.

"We will not be sharingpersonal data. Everything will be de-identified. So names, email addresses, your address, your ZIP code, your phone number, all that stuff will be stripped and will not be shared. We do want to still be very conservative because it is people's genetic data."

At 23andMe, individual-level data is never shared with a third party "without explicit additional consent from participants," Auton said.

"The information that we're talking about here, where we would be working with the academic community, is all aggregated at a very high level. So it's really just information about whether a specific genetic variant is associated with the disease. It doesn't contain any information about the individuals in the study."

Ball urged people to consider participating in this research for the common good.

"The people who came to AncestryDNA were interested in finding out about their ancestors, their past and their history," she said."This is our chancein this moment of history ... to take 5-10 minutes ... and do our best to help our community of friends or familyand the people who we don't even know who will be coming along later.

"It's our chance to contribute to the benefit of everybody. And I think right now, it'san opportunity that resonates with a lot of people."

Auton said the research could lead to therapies or treatments for people sickened by COVID-19.

"Hopefully, that can make a difference," he said.

Contact Kristen Jordan Shamus: 313-222-5997 or kshamus@freepress.com. Follow her on Twitter @kristenshamus.

Read or Share this story: https://www.freep.com/story/news/health/2020/05/26/genes-dna-ancestry-23-andme-coronavirus-covid-19/5223568002/

Link:
Genetic genealogy companies Ancestry, 23andMe begin COVID-19 research - Detroit Free Press

Did Neanderthals draw? This B.C. researcher is going to test DNA in old cave art to find out – CBC.ca

Victoria cave researcher, Genevieve von Petzinger,is suddenly ina pretty good positiontofind what she calls the Holy Grail of her field.

The University of Victoriapaleoanthropologist, who specializes in European cave art, has been awarded a National Geographic grant to test genetic material found in cave wall paint in Spain to try tofind out who forgot to sign their work at least 40,000 years ago.

A DNA test, which would reveal genetic mutations due to evolution, could help pinpoint the time perioda painting was made and may helpdetermine if the art was actuallythe handiwork of humans or Neanderthals who lived about130,000 to 40,000 years ago.

"'It would just be so fascinating to see the identity," said PetzingerTuesday on On The Island."The million dollar question is, did Neanderthals paint?"

And there is already someindication, according to von Petzinger, thatthis extinct species was, in fact, artistic.

Von Petzingersaid, a few years ago, some of her colleagues tested samples of minerals they foundcovering cave drawings and determined the minerals to be 65,000 years old, which von Petzinger said indicated the art underneath was older and, therefore, drawn byNeanderthals.

But, she said, this dating methodwas hotly debated by others in the field.

"It was quite the big drama going back and forth," said von Petzinger, who then thought maybe genetic testing could bea way to get a definitive answer.

Genetictesting can even pinpoint the artist's gender and, saidvon Petzinger, possibly lead to findinga living descendent.

"This would be a world first," she said, her voice brimming with excitement.

Von Petzingersaid she is incredibly grateful to colleagues, the Spanish government and National Geographic for being willing to believe in her "crazy idea."

But it's not without precedent.

She said other researchers havehad success testing genetic material found in dirt on the floor of caves in Croatia and she is "cautiously optimistic"she will have similar success with paint substances.

There is a bit of a snag though.

The money is in place, and all the players are on board, but it could be awhile before von Petzinger can board a plane.

She said her tentative plan is to be back in the caves, where she previously spentasignificant amount of time doing field work, by summer 2021.

The COVID-19 pandemic has thrown a wrench into field work for many academics, but von Petzinger said she is staying connected with colleagues online andit isa great time for scientists to slog through statistical analysis work they might as well get done while they can't get out.

And it could be because of her line of work, but von Petzingeris cautiously optimistic about the current state of the world aswell.

"This pandemic is certainly a pretty scary thing, but our ancestors have survived some pretty scary things themselves," she said. "Our species is very resilient."

To hear the complete interview withGenevieve von Petzingeron On The Island tap here.

Read the original:
Did Neanderthals draw? This B.C. researcher is going to test DNA in old cave art to find out - CBC.ca

Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients – Precision Oncology News

NEW YORK Employing tumor-normal sequencing, researchers have demonstrated that a significant number of advanced cancer patients learned germline findings that informed the treatment they received.

In one study, involving 12,000 patients treated at Memorial Sloan Kettering Cancer Center, researchers identified nearly 600 patients with recurrent or metastatic cancer who had actionable germline mutations, and 44 percent of them received targeted drugs either as part of the standard of care or as part of a research protocol.

Presenting the findings at the American Society of Clinical Oncology's virtual annual meeting, MSK's Zsofia Stadler said her group's study represents the most comprehensive assessment of the clinical utility of germline variants for guiding targeted therapy decisions in advanced cancer patients. This study, she said, demonstrates the "the importance of germline analysis for cancer treatment."

In another study, presented at the same meeting, researchers from the University of Michigan investigated the prevalence of actionable germline mutations in a cohort of around 1,000 patients, and found that 49 patients, or close to 5 percent, had therapeutically targetable germline mutations.

The findings from these two studies are timely given that cancer patients are increasingly having their tumors sequenced in the hopes of identifying precision therapy options. Studies have shown that after tumor profiling, approximately 10 percent of patients received results based on which they can receive precision drugs. Patients' tumors are often profiled using next-generation sequencing (NGS) panels that gauge hundreds of genes and also pick up clinically significant germline mutations, but often these findings are censored and not reported back to or discussed with the patient. This is likely because there is a perception that germline genetic mutations, which have been historically important for inherited cancer risk assessment, don't really impact the immediate care of patients.

"We know the identification of germline alterations has important implications for our cancer patients, including implementation of appropriate cancer surveillance measures, potential risk-reducing measures, and of course predictive genetic testing for at-risk relatives," said Stadler. "However, less is known about the clinical impact of germline findings on targeted cancer treatment."

At MSK, cancer patients can have their tumors profiled with the MSK-IMPACT NGS panel which gauges more than 400 genes. The goal of this testing, Stadler said, is to identify genetic mutations in the tumor that can be targeted with treatments. To do this, the cancer center sequences a patient's tumor tissue and normal blood sample, compares the detected mutations, and subtracts out the germline variants that occur in every cell in the body, not just the tumor. At the end of this process, only the somatic mutations found in the tumor are reported.

Starting in 2015, patients at MSK who received testing with MSK-IMPACT could provide consent under an institutional review board-approved protocol to receive separate germline testing for 88 genes associated with increased cancer risk. Between 2015 and 2019, nearly 12,000 patients agreed to this additional testing to learn if they harbored likely pathogenic or pathogenic mutations in any of these genes. If patients had pathogenic findings, this was noted in their medical record, which investigators then reviewed to assess whether the mutations could inform treatment.

Around half of these 12,000 tested patients had breast, prostate, pancreatic, or colorectal cancers, while the rest of the patients had a variety of rarer tumor types. Approximately 2,000 patients, or 17 percent, had likely pathogenic or pathogenic mutations, 682 of whom had mutations in high- or moderate-penetrance genes.

In terms of therapeutic actionability, Stadler and colleagues identified targetable mutations in 849 patients, or 7 percent. Since PARP inhibitors now can be given to patients with BRCA1 or BRCA2 mutations with certain types of cancers, mutations in these genes comprised more than half of the actionable findings. Nearly 20 percent of mutations were in Lynch syndrome genes, which can guide immunotherapy use.

MSK classifies the actionability of somatic variants detected by MSK-IMPACT using a three-tier system that emerged in the process of garnering FDA authorization for the panel. In authorizing that test, the FDA released a three-tier framework to help labs determine what information they could accurately communicate in test reports based on the evidence underlying detected biomarkers. The same system can also help oncologists prioritize which findings are most informative for their patient's care from the long list of genetic mutations often identified by these tests.

In the FDA's framework, tier 1 biomarkers are those that the agency has given companion diagnostic status based on evidence showing that they can determine which patients will or will not respond to a drug. Tier 2 biomarkers are "cancer mutations with evidence of clinical significance" that doctors can use in the care of cancer patients in line with guidelines and other information. Tier 3 biomarkers are "cancer mutations with potential clinical significance," which can help direct patients to clinical trials.

Since germline variations don't have a widely accepted system of classification for therapeutic actionability, Stadler and colleagues adapted this three-tier system for somatic variants to weigh the evidence on the 88 cancer risk genes. While 849 patients, or 7 percent, had targetable germline mutations in tier 1 and 2 genes, using all three tiers, around 1,000 patients, or nearly 9 percent, had germline mutations with therapeutic significance.

The researchers used the more stringent criteria germline mutations in tier 1 and 2 genes to try to guide treatment decisions for nearly 600 patients with recurrent or metastatic cancer. Ultimately, 44 percent received targeted drugs either as part of the standard of care or as part of a research protocol. Patients who received treatment had germline mutations in a variety of genes, though alterations in BRCA1 and BRCA2 drove a lot of the therapeutic decisions in the study.

As such, researchers explored this subset of patients in more detail. Of the 175 patients with BRCA1/2 germline mutations, 57 percent were classified as tier 1 mutations because patients had breast or ovarian cancer and were able to receive PARP inhibitors that had been FDA approved for their molecularly defined indication. More than 40 percent including 21 percent of pancreatic cancer patients and 11 percent of prostate cancer patients received PARP inhibitors under a research protocol. Since this study, however, the FDA has approved PARP inhibitors for BRCA-mutated pancreatic and prostate cancer.

"With the emergence of novel targeted treatments with new FDA indications, the therapeutic actionability of germline variants is likely to increase over time," Stadler said.

The study led by Erin Cobain from the University of Michigan similarly demonstrated the clinical utility of germline findings from tumor testing, though on a smaller scale. The researchers conducted targeted exome sequencing for 1,700 genes and transcriptome sequencing on tumor and normal samples from approximately 1,000 patients with advanced solid tumors. Pathogenic germline variants were identified in 160 patients, or 16 percent. Of the deleterious cancer risk mutations identified during this process, 92 percent were not known before patients were tested as part of this protocol, "which indicates that current clinical criteria may not identify all patients at risk for cancer predisposition," Cobain said.

Close to 5 percent of patients had biomarkers that could inform their treatment, such as defects in DNA repair genes, which can be treated with PARP inhibitors, and mutations in mismatch repair gene defects that can be used to prescribe immunotherapy. Significant proportions of patients with rare tumors had pathogenic variants, such as 20 percent of sarcomas, 17 percent of hepatobiliary cancers, and 16 percent of cancers of unknown primary. Cobain highlighted that some of these patients with these rare tumors had germline mutations that could potentially be therapeutically targeted, which is important given the limited treatment options in these settings.

Ultimately, 11 patients received PARP inhibitors and immunotherapies based on germline findings. Two patients had a complete response, one had a partial response, and five had stable disease. Of the three patients who had progressive disease, two were breast cancer patients with germline ATM mutations treated with PARP inhibitors, and the third was a pancreatic cancer patient with a BRCA1 mutation who received a PARP inhibitor.

The results of this study "support consideration of directed germline testing in all patients with metastatic solid tumors to identify defects in DNA repair with therapeutic targets," Cobain said.

To Funda Meric-Bernstam from MD Anderson Cancer Center, both of these studies demonstrate that if cancer centers are doing tumor/normal sequencing and looking for germline variants of clinical significance, they may not have to look too hard. However, she clarified that its also not "easy" to identify and report germline variants in this context. "This requires a lab to both analyze the normal [samples] and call pathogenic and likely pathogenic variants," she said.

Currently, there isn't a standardized method among tumor sequencing labs when it comes to dealing with germline findings. Some labs conduct only tumor testing, others conduct tumor-normal analysis but subtract germline findings, and still others perform tumor-normal testing and report only a subset of germline findings. Even if a lab sequencing only tumor tissue, tests will identify mutations in genes that are more likely to have occurred in the germline.

Meric-Bernstam noted that although the studies at MSK and the University of Michigan were done under IRB-approved protocols, in the real world when tumor sequencing is done, most patients aren't asked if they want to learn germline findings. "You really need infrastructure to return [results], to counsel, and to offer cascade testing," she said. "You need to facilitate the analysis of normal [samples] so you can ensure findings can be acted upon in a timely fashion, especially in patients with advanced disease. You need to have infrastructure in place for treatment matching and treatments available."

Though there are technical and infrastructural challenges to reporting out germline findings in the context of cancer tumor sequencing, genetics experts are increasingly of the opinion that it is no longer ethical to mask these findings, particularly given their increasingly important role in therapy selection as demonstrated by the ASCO studies. The American College of Medical Genetics and Genomics last month published a set of points that clinicians and genomics labs should consider when presumed germline variants are flagged during tumor sequencing.

Recognizing the varying practices in the field in this regard, the ACMG in its publication told genetic testing labs to be transparent about their ability to detect germline variants from tumor testing, as well as their reporting practices. Additionally, the ACMG told clinicians to take the opportunity when ordering tumor testing to evaluate the patient for clinical signs of an underlying hereditary cancer syndrome that may require germline testing.

According to Douglas Stewart, who is lead author of the ACMG paper and is a senior investigator within the National Cancer Institutes' Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, the aim of the association is to promote best practices. But it is also the association's hope, he recently said in an interview, that the issues laid out in the paper will start a discussion in the field about how "to capitalize on this huge opportunity of identifying germline variation in tumor sequencing so that it benefits as many people as possible."

Link:
Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients - Precision Oncology News

Prenatal and New-born Genetic Testing Market Inclinations And Development Status Highlighted During Forecast Period 2019-2025 – Cole of Duty

Prenatal and New-born Genetic Testing Market will exceed USD 7 billion by 2024; as per a new research report.

Technological advancement and several benefits associated with infant genetic testing will be major driver of the prenatal and new-born genetic testing market. Introduction of prenatal testing has led to substantial amount of increase in adoption rate of new testing technologies such as non-invasive prenatal testing (NIPT) for detection of sub chromosomal abnormalities, single-gene disorders and aneuploidy in North America region. Inclination towards minimally invasive infant genetic testing along with demand for early detection of birth defects will one of the major reason for market growth.

Rising number of consanguineous relations in the developing countries of Asia and Middle East will foster growth opportunities for prenatal and newborn genetic testing market. The consanguineous relations are responsible for births of infants with defects and chromosomal abnormalities. Consequent, the increase in cases of live births diagnosed with birth defects will directly impact the growth of prenatal and new-born genetic testing market.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/1906

Increasing prevalence of birth defects among the European population is one of the major reason for rising infant mortality. The necessary government initiatives in order to conduct prenatal and new-born genetic tests to diagnose the birth defects will increase the number of infant screening programs giving rise to market growth opportunities.

However, lack of infrastructure and skilled labor in the low and middle income countries will impede the parental and newborn genetic testing market growth. Moreover, ethical issues associated with prenatal and newborn testing coupled with incidences of false test results will further hamper industry growth.

Screening technology holds majority of market share in the year 2017 owing to increasing number of screening procedures of pregnant women while delivery. The rise in awareness among the families regarding genetic birth defects and early detection of genetic disorder will augment the segment growth in the near future.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/1906

Downs Syndrome recorded largest market share in the prenatal and newborn genetic testing market due to increasing in number of births diagnosed with Downs syndrome. The rise in incidences of women getting married at later stage of life is leading to increasing births with Downs Syndrome. These factors will further support the segment growth over the forecast timeframe.

Hospitals hold the majority of market share owing to increasing number of births in hospitals. Hospitals are aided by the government and provide the facilities require for the newborn screening. The increase in number of screening programs in hospitals provides significant scope for the market growth.

U.S. dominated the market in 2017 owing to ongoing technological advancements along with favorable reimbursement policies. The U.S. region had 99% of newborn screening rate and high awareness about prenatal and new-born genetic testing will be responsible for the market growth in U.S. Presence of technologically advanced and equipped manufacturing companies along with government initiatives supporting screening activities that will impel market growth.

Some of the major market players competing in global prenatal and newborn genetic testing market are Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health. The competitors are using launch of novel products with technological advancements, acquisitions and mergers as the key strategies to foresee a lucrative growth in prenatal and newborn genetic testing market. For example, In March 2018, Natera declared a partnership with QIAGEN to develop cell-free DNA assays for QIAGENs GeneReader NGS System. These DNA assays will be developed and designed for tests, including prenatal screening, for laboratories and hospitals globally.

Originally posted here:
Prenatal and New-born Genetic Testing Market Inclinations And Development Status Highlighted During Forecast Period 2019-2025 - Cole of Duty

Recent advances are transforming breast cancer treatment – Mountain Xpress

Womens relationship with their breasts is complicated. It includes apprehension about development, insecurity about size and shape, uncertainty about how to enhance/reveal/cover up/support them and then, post-middle age, concern about how well theyre holding up.

But nothing compares to the alarm felt when detecting a suspicious lump while taking a shower, the anxiety while awaiting the results of a mammogram or the heart-stopping terror triggered by the words Its cancer.

No one knows this more intimately than the medical professionals who interact with patients in the rapidly evolving field of breast health: geneticists, genetic counselors, radiologists, oncologists and nurse navigators.

Most breast cancers require a combination of different treatments, and the order and combination of those things is a whole lot more complicated today than ever before, says Dr. Blair Harkness, a gynecological oncologist at Hope Womens Cancer Centers, an arm of Mission Health. That is not a negative: We know so much more today about the different subtypes of breast cancer. Treatment is much more individualized, based on the biology of the different types of breast cancer.

You have to identify exactly what youre dealing with first, what kind of cancer, and then you can put together the plan and order of things. Its an important multidisciplinary team: genetics, surgery, medical oncology, radiation oncology, radiology, pathology. We all work together.

Dr. Jennifer McAlister, a breast surgeon at Pardee UNC Health Care, concurs. Each patient at Pardee receives multidisciplinary care, she explains. The entire breast cancer team is on one floor in the cancer center, so its easy for us to talk about specific cases. We also have a multidisciplinary tumor board that meets weekly to discuss all cancer cases. That team includes a radiologist, pathologist, medical oncologists, radiation oncologist, surgeons and palliative care.

Meanwhile, the current pandemic has further complicated efforts to diagnose and treat the disease (see sidebar, Breast cancer in the time of COVID).

Physicians encourage adult women of all ages to perform monthly breast self-exams. At age 40, women are advised to get a first baseline mammogram. Mission recommends an annual screening beginning at 40, because that reduces your risk of dying from breast cancer by 40%, says Dr. Sheri Fleeman, assistant medical director of breast imaging at Mission Health. One out of 6 breast cancers are diagnosed in the 40-to-49-year-old age range. Our goal is to find cancers early, treat them early and save as many lives as possible, and we feel like we can do that best if we start at 40 and do an annual.

There are exceptions, however. We recommend a baseline mammogram at age 40 unless a patient had a direct family member previously diagnosed with breast cancer, said Linda Richards, who has since retired as administrative director of cancer services at AdventHealth Hendersonville (formerly Park Ridge Health). For example, if a womans mother was diagnosed with breast cancer at 42, the recommendation for baseline for this woman would be 32: 10 years prior to the family members diagnosis.

Documenting family medical history is now standard procedure: For their first appointment at any practice, all new patients complete a lengthy questionnaire. When that information raises a red flag, patients may be referred to a genetic counselor.

Providers are becoming a lot more proactive asking about family history, and if there is cause, they may suggest an appointment at a genetics center, says Mission Healths Carolyn Wilson. We see people here for all types of indications, but the biggest area of growth, here and at all genetics centers, is in the area of inherited cancer, notes Wilson, one of six genetic counselors at the regions only such facility.

We know that about 10% of cancer is genetic, so its very common for people who either have a family history of cancer or a new diagnosis of breast cancer or another type of cancer to be referred to genetics. Determining if they might be in the genetic group, she continues, can certainly impact their screening, their treatment and medication choices.

Patients can expect the first appointment with a genetic counselor to run from 75-90 minutes. In addition to reviewing both personal and family cancer history, counselors will discuss the benefits and limitations of genetic testing. The process, says Wilson, is kind of complicated, and the results are not always black or white. We sometimes find an uncertain genetic change, which is not the same as a positive. You might not get a yes or no answer.

For those who decide to go ahead with it, the process involves either a blood or a saliva test. It takes two to three weeks to get the results, And if anything comes back positive or uncertain, we are happy to meet again to review the information, says Wilson. The report and a detailed letter are sent to them and their provider, so together they can map their next steps.

Even for those who test negative, however, the center creates a risk assessment based on personal and family history. Nongenetic factors that increase breast cancer risk include increased breast density shown on mammograms, having ones first period at a young age, having children later in life or not at all and hormone replacement therapy.

If a persons lifetime assessment risk for breast cancer is greater than 20% based on these computer-based models, they are recommended to follow high-risk breast screening, which includes an annual mammogram and breast MRI, notes Wilson.

And while mammograms are still the procedure most laywomen think of when it comes to getting naked and having your breasts squeezed flat between plates, breast imaging is a more accurate description of the many tools radiologists currently use to see the breast.

The 3D mammogram, explains Dr. David Onofrey of AdventHealths Medical Group Breast Center, creates a better image by pulling multiple X-ray images in just 10 seconds. A computer puts the images together, and this produces concisely focused three-dimensional images throughout the breast. Studies show that 3D mammography detects slightly more breast cancers than standard. AdventHealth, Mission and Pardee all perform this procedure.

At Pardee, notes McAlister, all mammograms are now 3D. In patients with dense breast tissue, we know that 3D mammograms find smaller masses or cancers that could be hidden on traditional 2D mammograms, she says. When the breast tissue is dense, it tends to overlap on itself and can be difficult to read. The 3D imaging allows us to view the breast in slices, so there is less risk of missing something small.

Another useful technology for women who have dense breast tissue a condition that, when discovered in a standard mammogram, must be reported to both physician and patient is the 3D whole breast ultrasound, or ABUS. The procedure, says Fleeman of Mission Health, uses sound waves to take 3D pictures of the breast. This is helpful because the breast is composed of fatty tissue and glandular tissue. The more glandular tissue you have, the denser your breasts. On mammograms, the fatty tissue is black and the glandular tissue is white. Cancers also show up as white, so in dense breasts, its like looking for a polar bear in a snowstorm. ABUS is a totally different way of looking at breast tissue, and in patients with dense breasts it can pick up cancers a mammogram might miss.

Yet another advanced tool is a breast MRI, which requires an IV to provide contrast. A more expensive test, its reserved for high-risk patients, says Fleeman.

If a tumor is detected, the next step would be a biopsy, and here too, advanced technology plays a role. The 3D-guided biopsy provides the radiologist with a clearer, more detailed image, allowing precise, accurate sampling of the tissue, explains Lisa Gundersen, clinical operations director of cancer services at AdventHealth. Its also more comfortable for the patient, she continues. AdventHealth, Mission and Pardee all offer this procedure.

For patients diagnosed with cancer, the interdisciplinary team develops an individualized treatment plan. Its not enough to simply say breast cancer anymore, notes Harkness. Its What kind? Because treatments we do are far more individualized for both the patient and the type of breast cancer were dealing with. So the first step is really understanding the imaging, the biopsy result and the subtype of cancer someone has, and then coming up with the best order and combination of treatment.

Most breast cancers, he continues, need some combination of surgery, radiation, chemotherapy and hormonal therapy; some cancers need all, but not every one. The order and combination depend on the subtype and the stage.

With new tests, says Harkness, oncologists can ascertain the tumors genetic makeup and, based on that, determine whether chemotherapy is likely to be effective. We use a lot less chemo for breast cancer than we used to, but hopefully were giving it more to people who will actually benefit from it. He adds that while some chemo regimens are harder to tolerate, thanks to better anti-nausea medications, the experience isnt nearly as bad as it used to be.

Despite the challenges, professionals engaged in the battle against breast cancer find reasons for optimism.

For Fleeman, the recent advances in sophisticated imaging are a key factor. We like 3D because we see better and its harder for the cancers to hide, she says. Our goal is to find and treat cancers early. With screening-detected cancer, the patient has to have less extensive surgery and less chemotherapy. When we find a cancer at Stage 1, its just a bump in the road.

Wilson, the genetic counselor, cites insurance companies increased acceptance of genetic testing. They used to look at it as kind of experimental, but now its really standard of care, because it can really make a difference financially and medically. If, through genetic testing, you can get someone the right treatment from the beginning versus failing five other treatments first, it makes a tremendous difference and impacts outcomes.

Harkness, meanwhile, believes, The biggest thing with breast cancer is how much research is being done. We have seen such dramatic strides in different areas of breast cancer over the last couple of decades; we are constantly refining and making advances. While nobody can know what that next thing is going to be, the trajectory of how much better we do in finding, treating and curing breast cancer today than we did even 10-15 years ago is where I find optimism.

Link:
Recent advances are transforming breast cancer treatment - Mountain Xpress

Impact of Covid-19 Outbreak on Direct-To-Consumer (DTC) Genetic Testing Market 2020 Trends, Growth Opportunities, Demand, Application, Top Companies…

A report, added to the extensive database of verified Market Research titled Direct-To-Consumer (DTC) Genetic Testing Market 2020 by Manufacturer, Region, Type and Application, Forecast up to 2026, is intended to highlight first-hand documentation of all the best implementations in the industry. The report contains an in-depth analysis of current and future market trends, segmentation, industrial opportunities and the future market scenario, taking into account the forecast years 2020 to 2026. It contains extremely important details on the key players in the Direct-To-Consumer (DTC) Genetic Testing market as well as growth-oriented practices, that they normally use. The report examines a number of growth drivers and limiting factors. The key forecast information by region, type and application with sales and revenue from 2020 to 2026 is included in this report.

Request Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=25584&utm_source=WCS&utm_medium=001

Top 10 Companies in the Direct-To-Consumer (DTC) Genetic Testing Market Research Report:

Competitive landscape:

The report examines the major players, including the profiles of the major players in the market with a significant global and / or regional presence, combined with their information such as related companies, downstream buyers, upstream suppliers, market position, historical background and top competitors based on the Sales with sales contact information.

Regional Description:

The Direct-To-Consumer (DTC) Genetic Testing market was analyzed and a proper survey of the market was carried out based on all regions of the world. The regions listed in the report include: North America (United States, Canada, and Mexico), Europe (Germany, France, United Kingdom, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina , Colombia etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa). All these regions have been studied in detail and the prevailing trends and different possibilities are also mentioned in the market report.

Sales and sales broken down by application:

Sales and sales divided by type:

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Direct-To-Consumer (DTC) Genetic Testing market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=25584&utm_source=WCS&utm_medium=001

Table of Content

1 Introduction of Direct-To-Consumer (DTC) Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Direct-To-Consumer (DTC) Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Direct-To-Consumer (DTC) Genetic Testing Market, By Deployment Model

5.1 Overview

6 Direct-To-Consumer (DTC) Genetic Testing Market, By Solution

6.1 Overview

7 Direct-To-Consumer (DTC) Genetic Testing Market, By Vertical

7.1 Overview

8 Direct-To-Consumer (DTC) Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/Direct-To-Consumer-DTC-Genetic-Testing-Market/?utm_source=WCS&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Read the original post:
Impact of Covid-19 Outbreak on Direct-To-Consumer (DTC) Genetic Testing Market 2020 Trends, Growth Opportunities, Demand, Application, Top Companies...

They Grew Up Believing They Were Half Brothers From The Same Sperm Donor. A DNA Test Revealed The Truth. – BuzzFeed News

Since he was born, Tylen has known he had a half brother on the other side of the country. In 2008, Tylens mother, Christy Coyle, had used the same sperm donor as the other mom, Lauran, and they found one another online. The kids were born weeks apart, met as infants, and played together. Their single mothers spoke weekly on the phone and raised them as half siblings so they would always have someone just like them whom they could turn to. For years, a large canvas photo print of Coyle holding the two boys hung on a wall in Laurans house.

We had planned that when they turned 18 and got to meet the donor that they were going to do it together, Coyle said. It was just our life plan.

With their children approaching 10, the two women paid for an AncestryDNA test to provide the boys with a piece of paper confirming their ties and breaking down their genetic history. One evening, while on the phone with Coyle, Lauran looked up the results.

And then it was just dead silence, Coyle said. There was no noise at all. And she just said, Theyre not related.

Coyle, now 41, was given the wrong sperm sample. The discovery sent her into a spiral. She felt violated, having been inseminated by a strange man whom she did not choose. She felt foolish, having searched in vain for physical similarities between the two boys. But she also felt that she had failed as a mother, as if she had betrayed her son and robbed him of the life plan she had envisioned.

It was a couple of months of just sitting there, being devastated for my son, she told BuzzFeed News. Lots of no sleeping or crying because you dont know what to tell your son. You feel like youve been lying to them about where they came from.

It would take months and a DNA test from an unsuspecting middle-aged woman living far away in Texas before the mystery would be solved.

Tylen, right, with Lauran's son as toddlers.

In the multibillion-dollar sperm bank industry, stories of mix-ups have become increasingly common. While federal regulators require that samples be tested for communicable diseases such as HIV, there is little to no national regulation beyond that: No laws punishing sloppy record-keeping at the clinics, no laws mandating that the personal information provided by donors is verified, no laws ensuring that women are being inseminated with the exact samples they have selected. And theres currently no major lobbying effort to change any of that.

Wendy Kramer cofounder of the Donor Sibling Registry, a website that connects children who were conceived using sperm donors said most people dont know how little the industry is regulated. I think for so many of us when we had to use a donor in order to have a child we all thought, Oh, its the medical industry. These are medical professionals, so theres going to be the same ethics and morals and responsibilities and record-keeping, she said. What many of us have come to realize over the years is this isnt the medical profession. These are sperm-sellers, and thats very different, and their ethics and responsibilities are very different.

The increasing ubiquity and availability of at-home DNA testing kits, genealogy websites, and social media has been a slow-building storm for the donor industry, gradually exposing more and more cases of samples or records being mishandled. Just as police departments are cracking decades-old cold cases using genetic testing, donor-conceived children are learning shocking information about themselves and their families.

The mistakes from clinics span the country and stretch back decades, taking a profound human toll not only on children such as Tylen but also on donor-conceived adults, shattering their understanding of themselves and their families as well as the bonds they have painstakingly built.

We obviously didnt grow up with one another, and we obviously didnt live close to one another, so that already makes it difficult to maintain a relationship, said Sam Johnson, a 29-year-old New Yorker who unearthed shocking information about his donor and his supposed half siblings after taking a DNA test. But then when you add the fact that were not even related, its like, whats really holding it together?

These stories from Coyle and Johnson touch on fundamentally human questions: What is family? And what is its purpose?

For most people, of course, family goes beyond simple blood bonds but involves social connections built over years of shared experiences. Its also a central means by which we get to know ourselves and build our identity.

For donor-conceived children, discovering new relatives with similar lived experiences can mean theyre extending their family in both the genealogical and social sense. The half sibling could fill in gaps in their biological identity and build a relationship that fills in part of their social identity and self-awareness.

Its hard enough for these donor-conceived people to kind of jockey around the whole idea of identity: Who am I when I dont know where half of me comes from? Kramer said. Connecting with others who also share that unknown half of yourself can be very important, can be profound and life-changing. Relationships are made, bonds are made, and friendships are made. Their family has expanded.

Then to have the rug pulled out under you, to say those people are not actually your biological relative, is extremely upsetting.

Johnson knew at an early age that his family was different. Born to two moms in the early 1990s, he grew up an only child in northern Manhattan. Liberal New York was something of a bubble, but kids were still kids. I definitely got shit ... Every time somebody would say, Oh, thats gay, I would fucking correct that, he said. People would definitely make fun of the way that I was born, the fact that I was conceived through artificial insemination.

He loved his moms, but there was an occasional nagging feeling a sense of mourning, as he described it, for not knowing exactly where he had come from. The only clue Johnson had was the donor information card from the New York clinic, Repro Lab, that his birth mother, Nicole Johnson, had used to conceive him. According to the donor sheet, Donor #19 was Italian, Catholic, and worked as a doctor. He had green eyes and dark brown hair. He was married and enjoyed soccer and antiques. He didnt smoke or drink, and he had a spotless medical history. Describes himself as, read the sheet, optimistic, exciting, and honest.

As he grew older, Johnson internalized what little information the paper provided him. He tried picking up some Italian using Duolingo and even had a friend teach him some recipes, soon perfecting the simple Neapolitan dish spaghetti aglio e olio. Occasionally, hed search online for doctors photos, wondering if he looked like any of the men in the results. In 2007, his googling led him to Kramers website, the Donor Sibling Registry.

Within a year, he had connected with a woman who had the same Donor #19 card from Repro Lab. And then another. And another. And another still. He was overwhelmed.

One of the women, Genna Ellis, was the same age as Johnson; she had grown up in Brooklyn, also with two moms. When she and Johnson met at Manhattans Union Square, what could have been an awkward encounter quickly eased into an hours-long walk as they discussed their similar childhoods. It was a powerful experience for both of us, considering that was the first time we thought we were communicating with someone we were blood-related to, Ellis said.

For the next decade, Johnson reveled in these newfound connections: A social worker by trade, he helped Ellis with an addiction problem. He visited one half sister in California when he helped a friend move across the country. He helped a third through a bad breakup and let her sleep on his couch. He was there when she got her first tattoo. She even came to his wedding.

I was always proud to be like, yeah, this is my sister to be able to say that, he said. I liked the idea of it.

The first crack came when one of the supposed half sisters took a 23andMe test and learned she had Baltic, not Italian, heritage. She later matched with a Slovakian man who confirmed he had been a donor at the New York clinic in his youth.

Johnson took a 23andMe test. Ellis took one too. None of them were related to each other. Their donors were all different.

It definitely hurt to find out that these relationships not to minimize their significance but to find out that the foundations that they were built upon were false, he said. Over the course of 10 years, I spent time forming relationships with these people. Not that they werent still meaningful, but its like the foundation is, like, what the fuck?

William Henry Pancoast (1835 - 1897). American physician and surgeon.

Secrecy and fraud have been present since the very first recorded case of successful artificial insemination in the US when in 1884, a 41-year-old wealthy Philadelphia business merchant and his 31-year-old wife came to see one of the citys most prominent physicians, William Pancoast. The doctor and his medical students inspected both and ultimately concluded the mans semen contained no sperm. After months of treatment failed, Pancoast came up with a plan B when one of his students joked that the only solution to this problem is to call in the hired man.

Pancoast invited the woman to his clinic and knocked her unconscious with chloroform. Then, without her consent and with his students present, the doctor used a hard rubber syringe to inject some fresh semen from the best-looking member of the class into her uterus before plugging her cervix with gauze. The students and Pancoast made a pledge of absolute secrecy.

She became pregnant, and Pancoast eventually felt guilty enough to tell her husband. He turned out to be delighted with the idea but asked that his wife not be informed. She later gave birth to a son. The insemination was only revealed 25 years later when one of the students, Addison Davis Hard, published a piece in a medical journal recounting the procedure. By all accounts, the woman was never told.

In the 1950s, scientific breakthroughs came with the freezing of sperm and the early pioneers immediately envisaged grand commercial potential. One of the first researchers in the field, Raymond Bunge, predicted in a letter to his mother, It wont be long before my icicles will be in the deep freeze section of supermarkets. But the research remained controversial; a 1954 headline about three babies born through Bunges method of freezing and insemination declared, Fatherhood After Death Has Now Been Proved Possible. Fear of so-called test tube babies abounded.

The first sperm banks didnt arrive until the 1970s, mainly as a place for men to deposit and store their own samples for later use, say, if they were going through cancer treatment. Fertility doctors were still mostly using fresh sperm samples not frozen ones to inseminate women. When the AIDS crisis began and several women contracted HIV from fresh donations, medical preference shifted for the first time to using frozen samples for the procedure. The only real regulation implemented involved screening the samples for STDs. But the list of diseases that are tested are relatively short, said Naomi R. Cahn, law professor at George Washington University and author of Test Tube Families: Why the Fertility Market Needs Legal Regulation. And for all we know the same donor that could be rejected at one bank is going to another bank and trying again until that donor succeeds.

There are no records of how many sperm donations are made every year in the US, nor of how many children are conceived, but it is frequently said to be between 30,000 to 60,000 births per year. Kramer with the DSR argues that number is woefully out of date.

Still, the scandals tend to find the media spotlight. There was the man whose samples were used to produce more than 150 children, the many parents who end up unintentionally having children of different races (in one instance because a clinic was said to have confused Donor 380 with Donor 330), the woman whose dead husbands samples were misplaced and allegedly used to impregnate other women, or the Georgia clinic that allegedly marketed a donor to hopeful parents as a neuroscience genius studying a PhD in engineering but who was in reality an ex-con who had never attended college and had a history of psychiatric hospitalization. His sample has been used to conceive at least 36 children.

Many of these mistakes would not have come to light had it not been for the arrival of the DNA genealogy market an industry estimated to be valued at over $3 billion in the US alone. Even if donors had requested decades ago to remain private, genealogy websites and social media have made that largely impossible. A 2018 survey of almost 500 donor-conceived people conducted by Kramers website found that almost a quarter of them had used DNA testing to track down their donor.

As more donor-conceived children find their biological parents and half siblings, new and extended family units are forming. One 2016 study of 419 donor-conceived children found more than a third of them get together once a year with the half siblings theyve discovered, and a fifth of them meet up together several times a year. Some 42% of them said they considered their half sibling to be part of their immediate nuclear family.

Tylen had been Christy Coyles miracle. In 2008, she was single and working in the records department of a police department in Chicago's suburbs when she was told she needed surgery to treat cervical cancer. If she wanted to ever have children like she had always dreamed, her doctor said, she needed to move quickly. She got to work.

Within three days, she had selected a sperm bank that would mail her a sample, NW Cryobank in Washington state, and begun printing out information sheets about possible donors, organizing them on the floor in stacks. She made lists of her preferred qualities blue eyes, blonde or brown hair, athletic, good eyesight, and above all healthy and circled donors who met her criteria.

Some nine months later, she was holding her son after he was delivered via C-section. He was just beautiful, she recalled through tears. It was like every dream that I had was in my hands, and I didnt think that was going to happen.

Using a forum on the sperm banks website, Coyle connected with Lauran, who was in South Carolina and had selected the same donor (Lauran asked that she be identified only by her first name and that her son not be named to protect their privacy). She, too, was a single woman now expecting a boy. I always thought that I would have a child in a marriage where I have somebody to share it with, said Coyle. And it was like she was somebody who, even though were just friends, she was able to understand what I was going through at the exact same time, and that was huge. It got me through a lot.

The connection deepened once the boys were born. Once they were here, we could see what they looked like and how big they were, said Lauran, now 44. We were constantly comparing: What size clothes is he in? Is he crawling yet? We went back and forth like that for years.

When the boys were almost 2, the families met. The two women booked adjoining hotel rooms in Atlanta and watched as the kids played together in parks and water fountains and fed each other fruit. Soon enough, the door between the two rooms remained open and the boys ran back and forth freely.

Coyle and Lauran's children playing together in the Atlanta hotel room

Despite living far apart, the families remained exceptionally close. Lauran and Coyle even decided to use another matching donor for their second children to further connect their families.

But when Lauran logged on to AncestryDNA during the phone call with Coyle one evening in 2018, they finally discovered the truth. A subsequent DNA test performed by California Cryobank which purchased NW Cryobanks assets in 2016 from another company, Cryo confirmed that only Lauran had been impregnated with the sample both women had requested. Coyle felt like all the planning shed done years ago, all her best intentions, had been for naught.

I thought I was doing what was best. I picked somebody who he would get to know when he turned 18. I had a piece of paper telling me what he looked like. I had all the information, and suddenly you find out none of that was true. You dont even know who you got, she said. Its a really hard thing to process. And you have to go back and really reevaluate if you made the right decision. I question myself a lot. It made me feel horrible.

There was grief, too. The vision the women had for their sons futures a half brother to call their own, a donor whom the boys could meet together when they turned 18 had disappeared. We thought, Well, if something were to happen, if the donor decided he didnt want contact, or he turned out to be a jerk, [my son] and Ty would have each other. No matter what, theyd have each other, said Lauran. And it just completely took that away from us.

Sitting on their couch in 2011 in California, Bryce Branzell and his new fianc, Ariel, were watching a TV show when one of the characters went to a sperm bank. The show brought up an old memory for Branzell, then 23, about the time hed almost donated to a clinic. When he told Ariel, they laughed about it. I was like, good thing you didnt! she told BuzzFeed News. We joked about it like, good thing you didnt and you dont have 10 kids out there!

In 2008, Branzell had returned from basic training with the Army Reserves in Montana. Money was tight. As he scanned the classifieds for jobs he saw an ad promising $500 for every sperm donation. It was easy money. He filled out an application detailing information about his physical condition, health, and education. Within a few weeks, he was called in to provide a sample so the clinic could test his fertility and determine if he could donate.

Thats when he started having doubts. He liked the idea of getting his fertility tested, but he still wasnt sure if he was comfortable with donating for real. When he turned up at the clinic for the awkward experience of masturbating into a cup, the nagging doubts were suddenly alarm bells.

At the time, I was thinking prior to this, Yeah, its a good idea. I like the fact that I can help a family have a child, he said. But then I actually got in there, and Im thinking about the long-term things that could potentially come from this and the fact that I want to have my own kids and how awkward it would be to say, Hey, boys, girls, guess what? Youve got an older sibling that you never knew about.

Branzell handed his test sample to the male technician and then apologized. He was backing out. He said he was assured his sample would be disposed of and he had nothing to worry about.

A decade passed. Branzell deployed to Afghanistan twice, first with the Army and then the Marines. He met Ariel. They married and moved to Texas, where he became a police officer in Round Rock. Ariel began flipping houses. Together, they had two boys: Conrad, 5, and Asher, 2.

Bryce Branzell and his wife, Ariel.

Then in January 2019, Branzell received a text message from his mother. She had been building a family tree and was given an AncestryDNA kit for her birthday. Now, a woman in Illinois had sent a message seeking medical information about her own son, who was conceived using a donor linked to Branzells mom. Had he ever made a donation before?

It was one of those moments where Im like, there has to be some sort of mistake here. Theres no way something could have happened, said Branzell. And then all of a sudden the thought popped in my mind that this did happen; I did provide a test sample to the company. Could that have been it?

Branzell began pacing the room as Ariel went to the womans Facebook account and began scrolling. She saw pictures of the womans son. She was shocked. He had the same chin and ears as her husband. She found photos of the boy as a baby. He looked just like their own son.

Branzell couldnt help but agree: She pulled up a picture of Tylen, he said, and I thought, Yep, he looks just like me as a kid.

A DNA test would later confirm it: Branzell was Tylen Coyles father.

The first phone call between Branzell and Tylen was full of awkward fits and starts. Hi, Im Bryce, he recalled saying to his son months later. Yeah, Im your dad? I guess? Maybe?

You could tell he was nervous about it. He wasnt as talkative, according to Christy, as he usually is, Branzell said. It was kind of awkward to begin with. Just, how do we handle this relationship now?

For both Branzell and Coyle, there is no guidebook for families suddenly joined together or, in the case of Sam Johnson and Genna Ellis, torn apart as a result of errors in the donor industry. Their relationship their understanding of what their family is is whatever they and their children want it to be.

How Branzells sperm sample ended up being used to conceive Coyles son is now the subject of a federal lawsuit. He is suing California Cryobank and Cryo for negligence, fraud, and infliction of emotional distress, among other things. (Reached for comment, lawyers for California Cryobank referred BuzzFeed News to their motion they filed on May 13 to dismiss the case. Cryo also filed its own motion to dismiss. Both companies argue they did not inherit NW Cryobanks liabilities when they purchased its stock and are not responsible for any wrongdoing.)

The Branzells had decided to contact Coyle the day after they learned of her request. Shed merely been asking for medical information about her sons donor, and they reasoned that if they were in her situation they would want the same. (Branzell has a history of blood clots, and the couple test their boys routinely.)

When the message arrived, Coyle felt like she could breathe again for the first time in months. It was a relief that oh my gosh, I finally know that at least there is a person and hes a real person that gave that donation, she said. I know it sounds dumb, but I was finally able to put a face with my sons other genetic half.

This hunt for medical information is also the driving force for Johnson in wanting answers about his donor. Hes a father himself now; he worries for his son, Phoenix, who was born last year with gastroesophageal reflux disease, despite it not running in Johnsons nor his wifes known family. What else could be lurking? He may have another rare disease that we could get tested, said Johnson, but I have no idea what the fucking medical history is.

Johnson knows that family is about more than DNA. He has good friends he considers to be Phoenixs uncles. And the relationships he built with the women he thought were his sisters still mean something to him; hes just not sure what.

I spent most of my life always wondering what the other side of me was, he said. You sort of start to piece together an identity based on this collective understanding of you guys having the same sort of situation and were like, oh, were related. We can form our own weird sober family thing! And then as soon as you start to do that and its taken away, it makes it feel like not necessarily that your time has been wasted but...yeah, it also does.

It definitely does feel like a loss, he said. It feels weird now if I were to contact them and try to talk to them, theres this voice in my head thats like, why? Not that theyre no longer important to me. I still care about them. Feelings like that dont go away, but I envision this cruel audience in my head being like, Youre being weird reaching out to these people. Theyre not even related to you.

In 2018, after he learned he was not related to his supposed half siblings, he wrote to Repro Lab, but the company said it no longer had the appropriate records on file. We understand how you feel, a company representative wrote back to him in an email provided to BuzzFeed News. There is a lot of confusion from the findings you described and we understand the emotions it has surfaced.

The reply infuriated Johnson. Have you been through this exact same experience? he told BuzzFeed News of their response. Then dont fucking tell me you understand. Im pissed.

Awilda Grillo, director of Repro Lab, told BuzzFeed News she could not say definitively what occurred in Johnsons case as she started working at the clinic after his mother ordered the sample in 1990. I dont know if it was an error in record-keeping, she said. Were talking about 28 or 29 years ago. Donor #19 was, I think, probably one of the first donors of the Repro Lab, and back then things were different.

She also suggested that the physicians who inseminated the different women may have made errors. You cant say because you have a piece of paper that you were inseminated with that donor. The only thing that could confirm that is the record of the procedure, Grillo said. I dont want to point fingers and say theyre guilty [or] were guilty. Who knows? Who knows whos guilty? But Im saying theres so many possibilities.

The New York Times reported last year in a story Grillo said was misleading that the New York State Health Department had found poor record-keeping at the clinic. The investigation was prompted when a woman discovered her 21-year-old daughter had been conceived using a sample from Repro Lab she had not originally selected.

Grillo said Sams story was unfortunate and upsetting, but she had no answers for him. Theres no clarity, she said. Theres a lot of unknowns, unfortunately.

In three states California, Indiana, and Texas so-called fertility fraud laws now make it a crime for a doctor to knowingly inseminate a patient with a donor whom they have not selected and given consent. These laws mainly came in response to doctors who used their own samples to impregnate unknowing women. (One Indiana doctor parented more than 60 biological children through this fraud.) But courts have been loath to find that families have suffered as a result of an accident or negligence as long as the child is healthy. The Utah Supreme Court called this the supposition that the road not taken would have led to a better result and described it a common human fallacy.

This was the judgment Coyle said she feared receiving in sharing her story with BuzzFeed News. It seems like the moms in these kinds of stories usually get responses like, You should be happy that you just have a healthy kid, she said. But they dont understand the emotional strain that it puts on you, and I think that they really need to change regulations and be held responsible for what they did.

Lauran, too, is sympathetic to her friends plight. Ive read stories of other moms. The judge kind of says, Youve got a healthy kid. What do you care? Well, because this is a person, and Ive been telling him one thing for 10 years and now Ive been lying unknowingly, she said. Hes a person. Hes not a product.

Months after the Branzells reached out to Coyle, the couples attorneys arranged for a meeting in Los Angeles. Ariel arrived first and had the awkward experience of meeting a total stranger who had given birth to her husbands child years before she had. Its just the weirdest, she said. Youre instantly connected, but youve never met them. You dont know any of their history, but you have this really strong connection.

It was there that Coyle pulled out her phone to FaceTime her son so he could speak to his father for the first time. She had waited until it was confirmed that Branzell was his donor before telling him about the mix-up. For Coyle, sharing the painful news that Tylen was not related to Laurans son was tempered somewhat by his excitement at knowing at last who his father is. He now peppers his mother with questions about Branzells work as a police officer and time in the military cool to almost any 10-year-old and wants to know if he, too, liked science when he was a kid.

Branzell, though, is taking it slow for now, at least. He and Ariel havent told their sons yet about their new half brother. He also doesnt know how many other children he may have out there, or how many times his supposedly discarded sample may have been used. He wonders what might happen if someone else turns up at his door at age 18 asking to be part of the family.

Still, he envisages a future relationship with Tylen one day. I know that he wants to have a relationship with his father, and it wouldnt be fair for me to say I dont want that, he said. Hes a kid, and I want to give him the things that he wants because he didnt get this choice. None of us did.

In South Carolina, Lauran also had to sit her son down and break the news about Tylen, but she isnt sure he really understands or has emotionally processed what happened. I dont know that he feels the full brunt of it just yet, she said.

But, she told him, Coyle and her boys are still family even if he is no longer related by blood to them. Ten years of bonds dont vanish overnight.

In her home, she still has on the wall the canvas photo print of Coyle and the kids, taken on that Atlanta trip in the hotel pool. Tylen wears a life vest, and Laurans son has floaties on as he reaches up to the camera for his mom. Coyle is beaming as she cradles them both.

Its just a good memory, said Lauran. I still think of it as when my son met his half brother, even though I know biologically its not true. Thats how I still like to think of it.

Excerpt from:
They Grew Up Believing They Were Half Brothers From The Same Sperm Donor. A DNA Test Revealed The Truth. - BuzzFeed News

Direct-To-Consumer (DTC) Genetic Testing Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud…

Over-the-Counter

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Direct-To-Consumer (DTC) Genetic Testing market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=248561&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Direct-To-Consumer (DTC) Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Direct-To-Consumer (DTC) Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Direct-To-Consumer (DTC) Genetic Testing Market, By Deployment Model

5.1 Overview

6 Direct-To-Consumer (DTC) Genetic Testing Market, By Solution

6.1 Overview

7 Direct-To-Consumer (DTC) Genetic Testing Market, By Vertical

7.1 Overview

8 Direct-To-Consumer (DTC) Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=248561&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Direct-To-Consumer (DTC) Genetic Testing Market Size, Direct-To-Consumer (DTC) Genetic Testing Market Trends, Direct-To-Consumer (DTC) Genetic Testing Market Growth, Direct-To-Consumer (DTC) Genetic Testing Market Forecast, Direct-To-Consumer (DTC) Genetic Testing Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Link:
Direct-To-Consumer (DTC) Genetic Testing Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud...

Fighting COVID-19: IIT Alumni Council Partners With Mumbai University For Its Megalab Project – NDTV

IIT Alumni Council Partners With Mumbai University

Image credit: Shutterstock image for representation purpose

A day after announcing the world's largest infectious diseases testing lab here to help fight the COVID-19 pandemic and other diseases, the IIT Alumni Council on May 29 said it has partnered with Mumbai University for the mega lab project.

The proposed MegaLab Mumbai, with a capacity to make as much as 1 crore tests a month, will be up and running from July with 1 lakh testing capabilities. It will reach full potential by early October, and will be the world's largest dedicated molecular diagnostic and genetic testing facility. MegaLab Mumbai will work with the National Centre for Nanosciences and Nanotechnology and the Innovation and Incubation Centre of the Mumbai University.

"The IIT Alumni Council is honoured to have the Mumbai University as its partner for enabling a world-class healthcare infrastructure in Mumbai for testing infectious diseases including the new coronavirus which has become a pandemic now.

"Under the partnership, the students, the faculty and the research infrastructure of the university will act as the research backbone of the MegaLab project, which will be based on the end-to-end Kodoy indigenous technology stack and will have adequate capacity for testing the entire population of Mumbai for infectious diseases, each month," said Ravi Sharma, the council president.

Mumbai University Vice-Chancellor Suhas Pednekar said, "Building on our strength in biotechnology and related research areas such as biosciences, we are now chartering a new path by partnering in a path breaking initiative promoted by the IIT Alumni Council to create one of the largest labs ever built for molecular diagnostic and genetic testing in Mumbai."

A global competition is underway to finalise more partners and also to identify the appropriate equipment sources, and consumable manufacturers. To enable the creation of an entire ecosystem to support the path-breaking initiative, MegaLab Mumbai will be partnering with research-oriented institutions of national importance in Mumbai and Delhi, Sharma said. The partnership with Mumbai University will ensure consistency, speed, quality and scale of MegaLab testing, he said.

The council has been on the forefront of catalysing and motivating students, professionals, corporates, startups and academicians to align their energies in the quest to find innovative, low-cost and rapidly scalable solutions for the pandemic.

The council has already developed 100 per cent indigenous kits which are in various stages of manufacturing and approvals so as to meet the entire requirement of developing countries, including India, China, Asean nations, the Middle East, Africa and Latin America.

MegaLab Mumbai is the biggest initiative of the council to date and aims to help design and establish the largest genetic testing laboratory for the new coronavirus and other infectious diseases like TB with an end-to-end capacity to carry out over 1 crore tests per month.

Ravindra Kulkarni, the pro-vice-chancellor of Mumbai University, said the varsity has an outstanding track record in the area of biological and medical sciences. "Several doctors who are at the forefront in the fight against new coronavirus have been our alumni and we take pride in their contribution," he said.

(with PTI inputs)

IIT Alumni Mumbai University VC covid pandemic

Read this article:
Fighting COVID-19: IIT Alumni Council Partners With Mumbai University For Its Megalab Project - NDTV

Covid-19: IIT Alumni Council, Mumbai University to partner for MegaLab Mumbai initiative – The Indian Express

By: Express Web Desk | New Delhi | Published: May 29, 2020 8:00:22 pm Keeping in mind the opportunity to replicate with smaller capacities at other places in India and in other developing counties, the MegaLab will comprise of three independent lines, namely 1 million tests per month (tpm), 3 million tpm and 6 million tpm.

The IIT Alumni Council Friday announced that the alumni body will be partnering with Mumbai University for the MegaLab Mumbai Initiative.

According to a press release by the alumni council, MegaLab Mumbai is the biggest Covid-19 initiative of the IIT Alumni Council, which aims to help design and establish the largest genetic testing laboratory for Covid-19 and other infectious diseases with an end-to-end capacity to carry out over 10 million tests per month.

Keeping in mind the opportunity to replicate with smaller capacities at other places in India and in other developing counties, the MegaLab will comprise of three independent lines, namely 1 million tests per month (tpm), 3 million tpm and 6 million tpm.

The release stated that a global competition is being launched to identify sources for equipment, consummable manufacturers and operating partners. The lab has also proposed to work with National Centre for Nanosciences and Nanotechnology and the Innovation and Incubation center of Mumbai University. The alumni of IITs and alumni companies will work with the students, faculty and alumni of Mumbai University.

IIT Alumni Council is honoured to have Mumbai University as its partner for enabling world class healthcare infrastructure in Mumbai for testing and treatment of infectious diseases including Covid19. The students, faculty and research infrastructure of Mumbai University will act as the research backbone of the MegaLab project . MegaLab will be based on the end-to-end Kodoy indigenous technology stack and will have adequate capacity for testing the entire population of Mumbai for infectious diseases, each month said Ravi Sharma, President of IIT Alumni Council. This partnership will ensure the consistency, speed, quality and scale of MegaLab testing, he added .

Commenting on the partnership, Professor Suhas Pednekar, the Vice Chancellor of University of Mumbai said, With a 160+ years history of excellence in academics, University of Mumbai has been a pioneer in research work across multiple disciplines. Building on its strength in biotechnology and related research areas such as biosciences, it is now chartering a new path by partnering in a path breaking initiative promoted by the IIT Alumni Council to create one of the largest labs ever built for molecular diagnostic and genetic testing in Mumbai with a capacity of 10 Million RTPCR tests per month.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Delhi News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read more from the original source:
Covid-19: IIT Alumni Council, Mumbai University to partner for MegaLab Mumbai initiative - The Indian Express

Looking for loons: Isolated birds widely recognized as indicator species of healthy aquatic environment – Sports and Weather Right Now

The memorable scenes of loons in the 1981 movie On Golden Pond were my first introduction to common loons, but it would be more than 30 years before I saw one in person.

While kayaking with my husband at a Northeast Washington lake five years ago, we could hear their legendary haunting and eerie call. A large male common loon then swam into view, and my fascination with loons began.

As a nature photographer, I was drawn to these unique, beautiful and interesting birds.

The striking appearance and haunting call of the loon are legendary. Their plumage has intricate patterns of black and white on their bodies; a dark multicolored collar, a head and partially striped neck that are iridescent when washed in sunlight.

And those piercing red eyes.

Loons breed throughout most of Canada and northern United States. They migrate to salt water or large fresh water large lakes and rivers in winter, returning to the same nesting and migration sites each year. Loons are monogamous, but will seek out a new mate if their mate doesnt return in the spring. The lifespan of a healthy loon is up to 30 years.

Both male and female loons build their nest, incubate eggs, and care for young. Their tender devotion to their chicks is one of the most remarkable scenes I have witnessed in the natural world, and a trait that endears them to many. Chicks ride on their parents backs for the first couple of weeks after hatching.

In 2018, I was fortunate to witness this for the first time. The chick climbed onto the parents back using the tail like a ramp or going up under the parents wing. The little chick sat warm and safely protected, peering out from under the shelter of the wing, an image that remains forever etched in my mind.

Ive since viewed and photographed newly hatched chicks on multiple occasions, and the experience always leaves me in awe.

Their diet consists of fish, crayfish and aquatic invertebrates such as dragonfly nymphs. Loons swim along the surface of the lake with their head and necks underwater scanning for fish, shooting like a torpedo underwater after their prey. The parents feed chicks until they migrate in the fall.

While I was once focused on getting the shot, the motivation behind my work has changed over time. I began researching the creatures I was photographing to learn more about them, and in the process have come to really care about what I photograph and the challenges they face. Advocacy and teaching others about the subjects in my images are now an important part of my work.

There is often a story behind the scenes I photograph. Such is the case with loons. It turns out that seeing loons is a special thing indeed. Loons once nested in Washington, California, Idaho and Oregon, but today they are only known to be nesting in Washington. Historically, there were 50 known nesting pairs in Washington state. That number is much smaller now. The majority of nesting loons are in Northeast Washington, with just 16-20 nesting pairs there.

A loon pair has a clutch of one or two eggs per year. Few loon chicks survive to the end of summer to migrate. In 2000, Washington Department of Fish and Wildlife listed them as a sensitive and threatened species. Factors affecting their recovery are predation by other animals and birds, habitat loss, lead and mercury poisoning, and human interference.

In 1980, there were just 104 bald eagle breeding pairs in the state, but by 2005 had recovered to 840, continuing to increase since that time to the point that they have been removed from both the federal and state endangered species lists.

As predators, eagles sometimes prey on both loon chicks and adults a factor in building a sustainable loon population. Loons also ingest lead fishing tackle from broken fishing lines, resulting in lead poisoning. Regulations banning lead tackle at lakes where loons nest has helped, but non-nesting lakes that still allow lead tackle continue to affect mortality in transient or migrating loons.

Human interference is complex. Some loons are struck by boats or jet skis. At least nine waterfowl species eat fish in Eastern Washington, but there are a handful of people who object to loons eating fish, shooting them or intentionally destroying their nests.

Well-intentioned nature lovers and photographers also put them at risk by getting too close, driving loons from their nests or disrupting their nesting/chick raising in some way. Loons show distress by moving away from feeding chicks, leaving the nest, theatrical acrobatics in the water or alarm calls.

If your presence changes their behavior in any way, you are too close.

I have been fortunate to meet and learn from Dan and Ginger Poleschook, two volunteer researchers who have dedicated the last 25 years to Washington loon conservation work and advocacy, and have been instrumental in loon recovery.

Last summer, I joined them for loon banding at a remote Ferry County lake. Banding occurs late at night when all traces of light are gone a necessity for successful loon capture.

To an outsider, it probably looked like a clandestine drug operation, but it was actually a team of experts from the Forest Service and Biodiversity Research Institute working together on behalf of the loons.

Loons were captured and brought back to a staging area on shore, where the team drew blood to measure heavy metal levels, collected feathers for genetic testing and measured, weighed and banded the loons. A large male was caught first, and then later the female with a chick.

While the female was processed, Ginger held the tiny days-old chick in her hands. The team repeated this process nearly every night, covering nine lakes in Eastern Washington. They were knowledgeable and efficient, with an infectious camaraderie and passion for loon conservation.

Though we wrapped up around 3 a.m., I was energized by this unforgettable experience. It gave me a greater awareness that there is often much happening behind the scenes to preserve the wildlife many of us treasure.

Because of their longevity and place in the food chain, common loons are widely recognized as an indicator species that reflect the health of the aquatic environment, which in turn impacts human health.

Ameritrade founder Joe Ricketts Conservation Foundation made a substantial donation to support loon conservation and relocation of the common loon to former nesting areas where they have been eliminated. Ricketts believes the loons on our lakes and streams are similar to the canary in a mine.

If were polluting our lakes to the point where were killing the loons, its a wake up call to us as human beings that were causing more damage to our environment than we think we are and we cant see it except through a bird like the loon, Ricketts said.

Loons are dependent on our choices for their continued survival. As Maya Angelou once said, When we know better, we do better. As much as I love photographing loons, their survival is more important than any experience I might have or image that I take.

This has translated to changes in how I observe and photograph loons quietly observing loons from a distance to avoid disturbance, backing away if their behavior changes or they show signs of distress. I come back at another time if I see other people are already observing loons on a lake. The purchase of long lenses and cropping has helped to get close-up shots while maintaining a respectful distance.

I advocate for and educate others about loons when there is an opportunity. Weve replaced fishing gear with nonleaded tackle, and make every attempt to remove lines that have become snagged. These small things make a difference.

The loons are returning to Northeast Washington and nesting season is upon us. Understandably so, many people love loons and their unforgettable haunting call. My hope is that in knowing the loons plight, we all do what we can to protect these magnificent birds, so that we can continue to enjoy them for generations to come.

The loons just might have a bigger role in our lives than we think. A win for the loons is a win for us all.

View original post here:
Looking for loons: Isolated birds widely recognized as indicator species of healthy aquatic environment - Sports and Weather Right Now

Consumer healthcare choices and options to be an outcome of COVID-19 pandemic – Reno Gazette Journal

Dr. Bonnie Ferrara talks about how Renown Medical Group is offering virtual doctor visits for certain patients. Reno Gazette Journal

The ball has bounced to the patients court

Thats at least according to Renown CEO and President Anthony Slonim,who said the outcome of the coronavirus pandemic means consumers will have more options and choices.

And those options are coming faster than ever before in a medical world that was sometimes been slow to transform to patient needs.

We have been doing it around the edges, said Slonim about the incremental progress the medical community made on population health and consumer-driven healthcare.

Overnight our world has shifted to make us think more deliberately about how we can go about executing it.

Slonim said the expansion of telemedicine happened literallyovernight in Nevada as patients with other illnesses avoided doctors offices and urgent cares for fear of contracting coronavirus.

We are learning that people want convenience in their living rooms.

He saidtelemedicine is the just one of the ways consumers are demanding options.

He said now when a person is sick they can decide if they need to Skype a doctor.

Do they need to have a nurse practitioner visit them at home or do they need to go to an urgent care or the ER?

Slonim said medicine is changing and giving concierge service to everyone.

Slonim also said the problem in medicine had been there hasnt been a quarterback.

Now some of that ownership is back on primary care physicians.

I am telling doctors, 'Dont wait for them to come to you,' he said. You have to manage it.

Dr. Bonnie Ferrara of the Renown Medical Group poses for a portrait while using the Zoom app on her computer on May 20, 2020. This is how Dr. Ferrara would appear to patients during a virtual medical consultation.(Photo: JASON BEAN/RGJ)

He also said health care will need to learn to relinquish some of the control.

We learned that with our Healthy Nevada Project, Slonim said of an initiative pioneered by Renown to genetically test thousands of Nevadans to evaluate the health of the population.

When we made genetic testing free, 50,000 people signed up, he said.

He said the same is true of COVID-19 testing.

Everyone you talk to wants a COVID test, he said. Opening it up to everyone without a doctors prescription puts consumerism more front and center than ever before.

He said it gives families and individuals choices on how to manage their own health.

There are safe and appropriate things you can do without having to go to a doctor, he said. Needing a doctors prescription for tests is old school thinking.

And while the image of coronavirus focused on social distancing and doctors covered head to toe in protective equipment, Slonim said the pandemic has the medical community talking about the human touch.

During a recent medical webinar, Slonim said the conversation was that technology cant be everything.

Remember when it was OK to sit on the bed with a patient and hold their hand, Slonim said a doctor on the call said.They talked about how it became common to view that as invading a patients space.

But Slonim said people still long for that connectivity and caring.

What will evolve is a way to understand how to do that differently with technology enabling it.

3 ways healthcare will change for patients

Siobhan McAndrew tells stories about the people of Northern Nevada and covers education in Washoe County. Read her journalism right here. Consider supporting her work by subscribing to the Reno Gazette Journal.

Read or Share this story: https://www.rgj.com/story/news/2020/05/28/renown-ceo-healthcare-coronavirus-pandemic-covid-19-cases-telemedicine/5231946002/

Read more:
Consumer healthcare choices and options to be an outcome of COVID-19 pandemic - Reno Gazette Journal

As North Dakota wildlife goes, mountain lions top the list of species that captivate and fascinate – Jamestown Sun

Ask anyone in North Dakota wildlife circles, and theyd likely be hard-pressed to name an animal that generates a bigger buzz than a mountain lion that makes its presence known.

It depends on a persons passion but mountain lions do even for the nonhunting public garner a lot of interest from people, said Stephanie Tucker, furbearer biologist for the North Dakota Game and Fish Department in Bismarck.

That definitely was the case in late March, when authorities in West Fargo shot and killed a treed mountain lion that was deemed potentially dangerous near a local park. The cat was a long way from the core of North Dakotas mountain lion breeding range in the Badlands and Little Missouri River Breaks.

Theres way more, say, deer hunters in North Dakota that are passionate about deer hunting and follow whats going on with deer, Tucker said. But if youre not a deer hunter, you dont really care about deer and might not be fascinated by them.

Whereas, theres just a lot of people, regardless if theyre hunters or not, that are fascinated by mountain lions.

Stephanie Tucker, furbearer biologist, North Dakota Game and Fish Department. (Photo/ North Dakota Game and Fish Department)

Tucker gave an update on mountain lions in North Dakota during the Game and Fish Departments recent spring advisory board meetings for hunters and anglers held online because of COVID-19 and further discussed the iconic cats this week in a telephone interview.

Bottom line, mountain lions in the core of their western North Dakota range are holding at a level thats low but steady and acceptable both to wildlife managers and landowners, Tucker says.

Were not hearing a lot of concerns from ranchers or deer hunters who dont like to share deer with mountain lions and things like that, she said. I definitely feel, from my perspective, that weve found a very comfortable situation where were between everybodys expectations, and the population is sustaining itself at a healthy level at the same time.

In his book, The Mammals of North Dakota, UND Professor Emeritus of Biology Robert Seabloom writes that mountain lions historically occurred across the Great Plains but never were common.

There were no early records of mountain lions in eastern North Dakota, and cats that historically inhabited North Dakota west of the Missouri River had disappeared by the early 20th century, the book states.

The population likely was so low that mountain lions in North Dakota were undetectable to most people, Tucker says.

They were likely extirpated or close to there, she said. They dont have high reproductive rates. A female only produces a litter every other year, and theres probably only two kittens in each litter so it just takes a while for the population to build itself.

According to The Mammals of North Dakota, mountain lions started gaining a foothold in the western part of the state in the 1950s. By 2005, the Game and Fish Department deemed the population high enough to offer an experimental hunting season.

Game and Fish manages mountain lions by dividing the state into two zones: Zone 1 in the Badlands area encompasses the core breeding range, while Zone 2 in the rest of the state is less suitable for the cats.

North Dakota Game and Fish Department

North Dakotas mountain lion population peaked in 2011 or 2012 at a range somewhere between 100 and 275, based on results from computer modeling, Tucker said. In response, Game and Fish upped the harvest quota for cats in Zone 1 to drive the number down and slow the increase.

Current models suggest a population in the range of 50 to 60 cats.

Once the population came back down, we backed off on our hunting season harvest limits a little bit, and the population has been fairly stable, with minor fluctuations up and down from year to year, since that time, Tucker said.

Hunters shot 14 mountain lions in Zone 1 during the 2019-20 season and three cats in Zone 2. Since the inaugural season in 2005, the statewide harvest has ranged from as low as four to as many as 19 during the 2017-18 season, when a record six cats were taken in Zone 2 outside the core breeding range.

The Fort Berthold Indian Reservation also offers a season but works with Game and Fish in sharing information to manage the species, Tucker says.

North Dakota Game and Fish Department

In an effort to learn more about the high number of cats taken in Zone 2 during the 2017-18 season, Game and Fish contracted with the U.S. Forest Services Rocky Mountain Research Station in Missoula, Mont., to conduct genetic testing on mountain lions killed outside their traditional range, Tucker said.

We really got to wonder, Are these mountain lions that are coming from our breeding population, or are they coming from somewhere else like the South Dakota Black Hills or one of the mountain lion populations in Montana? she said.

Results from that testing showed about 50% of the dispersing cats came from South Dakota, 25% from Montana and the remaining 25% from North Dakota.

The numbers dont account for cats that either pass through the state safely or travel through undetected.

This is just the ones that are taken by hunters or hit by an automobile or something along those lines, she said.

Mountain lions are well known for traveling long distances, Tucker said, especially young males, a trait believed to be natures way of preventing inbreeding within a population.

Mountain lions really have turned up in all corners of the state, she said.

Results from the genetic testing have helped the department build on the knowledge base it gathered on mountain lions during a GPS tracking survey that began in 2011 and wrapped up in 2017.

As part of the survey, a partnership with South Dakota State University, Game and Fish staff and SDSU graduate students trapped and fitted 14 mountain lions with GPS collars, while 22 cats received ear tags.

The collars were programmed to provide tracking information every three to six days, Tucker said. None of the cats collared in the survey permanently dispersed from the Badlands, although a couple of cats did venture off before returning, she said.

A mountain lion in western North Dakota wears a GPS tracking collar as part of a study the Game and Fish Department conducted beginning in 2011 and continuing through 2017. As part of a study with South Dakota State University, 14 mountain lions were fitted with GPS collars and another 22 with ear tags. (Photo/ North Dakota Game and Fish Department)

Results from the GPS collar survey helped the department fine-tune the modeling it uses to determine population trends for mountain lions in the state. Other factors used to determine population trends include the age of cats taken by hunters, who are required to submit the carcasses to Game and Fish, and genetic analysis.

Mountain lions dont lend themselves to a lot of our traditional survey techniques, Tucker said. We cant do a roadside survey and expect to see a mountain lion. We cant get up in an airplane and do an aerial survey and expect to see a mountain lion. Theyre nocturnal, they exist in low densities on the landscape, they have large home ranges and so we really rely on a population model to tell us what the population trends are.

In other words, its not about specific numbers.

I cant stress that enough, Tucker said. People always ask me, How many mountain lions do you think we have in North Dakota? And I say I dont know.

What is known is that mountain lions conceivably can wander through any part of North Dakota at any given time. As a ballpark estimate, Tucker says Game and Fish gets 25 to 30 reports of mountain lion sightings every year in North Dakota, of which maybe one-half to one-third can be verified.

Im always fascinated, too, she said. One of the reasons we know that mountain lions are in eastern North Dakota is because of reports from the public like trail camera photos or somebody snaps a picture of one and it was there and gone.

Tucker encourages the public to report sightings using the departments online furbearer reporting form at https://gf.nd.gov/hunting/furbearers/rare-furbearer-observation.

Dokken reports on outdoors. Call him at (701) 780-1148, (800) 477-6572 ext. 1148 or send email to bdokken@gfherald.com.

Read the original:
As North Dakota wildlife goes, mountain lions top the list of species that captivate and fascinate - Jamestown Sun

Predictive Genetic Testing and Consumer/Wellness Genomics Market Estimated to Experience a Hike in Growth by 2025 – Cole of Duty

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Estimated to Experience a Hike in Growth by 2025 - Cole of Duty

Global trade impact of the Coronavirus Direct-Access Genetic Testing Market Size Overview, Top Companies, Inventive Trends and Forecast to 2029 – 3rd…

Detailed Study on the Global Direct-Access Genetic Testing Market

A recent market study throws light on some of the leading factors that are likely to influence the growth of the Direct-Access Genetic Testing market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current Direct-Access Genetic Testing market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.

As per the report, the Direct-Access Genetic Testing market is forecasted to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key dynamics of the Direct-Access Genetic Testing market including the drivers, restraints, opportunities, and trends are thoroughly analyzed in the presented report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601843&source=atm

The Research Aims to Addresses the Following Doubts Pertaining to the Direct-Access Genetic Testing Market

The report on the Direct-Access Genetic Testing market provides a birds eye view of the current proceeding within the Direct-Access Genetic Testing market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Direct-Access Genetic Testing market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Direct-Access Genetic Testing market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601843&source=atm

Direct-Access Genetic Testing Market Segmentation

Competitive Landscape

The competitive landscape section of the report elaborates on the recent developments and innovations introduced by prominent players in the Direct-Access Genetic Testing market. The growth potential, revenue growth, product range, and pricing strategies of each market player in inspected in the report with precision.

End-use Industry Assessment

The report segments the Direct-Access Genetic Testing market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the Direct-Access Genetic Testing in each end-use industry.

The key players covered in this study23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull Genomes

Market segment by Type, the product can be split intoDiagnostic ScreeningPGDRelationship testingMarket segment by Application, split intoOnlineOffline

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Direct-Access Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Direct-Access Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-Access Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601843&licType=S&source=atm

Essential Findings of the Direct-Access Genetic Testing Market Report:

See the original post:
Global trade impact of the Coronavirus Direct-Access Genetic Testing Market Size Overview, Top Companies, Inventive Trends and Forecast to 2029 - 3rd...

The benefits and the costs of home DNA tests – Health and Happiness – Castanet.net

Photo: Contributed

Is the wealth of information about your individual health risks worth the anxiety of knowing?

DNA testing kits have made it possible to access previously unmined information about your health. As a huge advocate of preventative medicine, Ive explored the pros and cons of accessing this wealth of information to see whether your spit is worth the price tag and the consequences.

Firstly, what is it? Companies like 23andMe offer a home-based saliva collection kit you spit in the tube and send it to the lab. From there, your DNA is extracted from the spit and a process called genotyping analyses the DNA.

You then receive a report with your health predispositions (diseases you are more likely to get due to your genes) and your carrier status of certain diseases, such as cystic fibrosis.

The most obvious benefit of getting your DNA tested is identifying your personal health predispositions. For instance, the report might indicate youre at risk of getting type 2 diabetes, or heart disease. With this information, you can make changes to your lifestyle to help prevent these diseases from occurring, such as quitting smoking, drinking less caffeine or eating less sugar.

Despite these benefits, it is important to consider the emotional stress of receiving unfortunate results. Finding out you are at high risk of Alzheimers has a huge emotional impact on an individual and their family, especially as there is little you can do to prevent it.

Personally, I wouldnt want to know Im at high risk for a disease I cant do anything about I think the anxiety the knowledge would cause wouldnt be worth the information.

Its also important to note that genealogy results arent definitive. For instance, they may identify the gene that can cause high cholesterol, which in turn can increase the risk of heart disease. However, the test doesnt take into account any other personal or environmental factors, such as your diet, exercise and lifestyle. Without input from your own family doctor or a genetic counsellor, the results cannot be taken as gospel.

The uses of genealogy DNA databases extend beyond personal use for health and ancestry information, and this is the part where I begin to question the safety of using these kits. Although companies have rigorous privacy policies, they do still keep your DNA and information in a database in order to identify future clients that may be within your family tree.

This data is vulnerable to hackers, but also to police and immigration officials. The CBSA uses genealogy DNA testing in an immigration setting to ascertain a persons identity, such as the country they originate from.

From the uses we know about, to those yet to be found Im not sure I want my DNA in a database with unknown potential.

There are also important financial implications that accompany genetic testing, such as the fact that some insurance companies now say you must disclose any genetic risk information you are aware of, which can mean higher premiums for health, life and travel insurance.

Having mused over the idea for several weeks, with my mouse hovering over the Add to Cart button more than once, Ive decided genetic testing is not for me, for now. I personally dont think you should need a genetic test to tell you to live a healthier lifestyle to exercise more, eat more greens and get better sleep.

If its something youre thinking about, or have done, I would love to hear your thoughts on it. If not, take it from me get out for a cycle or a run, spend more time with your family and eat some broccoli with a smile on your face.

More here:
The benefits and the costs of home DNA tests - Health and Happiness - Castanet.net

Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. – GlobeNewswire

SALT LAKE CITY, May 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel K. Spiegelman, age 61, to its Board of Directors, effective immediately, expanding the Board to nine members. Additionally, Mr. Spiegelman was appointed to the audit committee of Myriads Board.

Mr. Spiegelman has served as a Chief Financial Officer in several diversified biotechnology companies spanning 30 years. He was most recently Executive Vice President and Chief Financial Officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on development of first-in-class and best-in-class therapeutics for rare genetic diseases. Having retired from that position after eight years, Dan now serves on the board of Tizona Therapeutics, Inc., a private pharmaceutical company, and has previously served on a number of public and private biotech company boards.

We are excited to welcome Dan to the Myriad Board, said Louise Phanstiel, Chair of the Board of Myriad. Dan brings a deep understanding of the biotech industry along with strong finance, M&A and business development experience. His background of creating value and growing early stage as well as established companies will provide useful strategic insights in executing our global strategy for molecular diagnostics and precision medicine.

The Company also announced today that Director John T. Henderson, M.D. will retire from the board at the Companys Annual Meeting in December 2020. Dr. Henderson joined the Board of Myriad in 2004 and has served as Chair of the Board from April 2005 through March 2020.

It has been a privilege to play a part of Myriads journey in becoming a leader in providing trusted healthcare advice to patients and their physicians, said Henderson. I have treasured the opportunity to work with so many Myriad employees whose passion and dedication to pioneering best of class precision medicine is unsurpassed. I certainly look forward to the companys continued growth and success.

In commenting on Dr. Hendersons pending retirement, Louise Phanstiel said, The Board sincerely appreciates all of Johns many contributions to Myriad as a leader, a colleague and friend. John has led with integrity and caring about Myriads Vision and Mission. He will be deeply missed and we wish him all the best.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Lynparza is a registered trademark of AstraZeneca.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Mr. Spiegelman providing useful strategic insights in executing the Companys global strategy for molecular diagnostics and precision medicine; Dr. Henderson retiring from the board at the Companys Annual Meeting in December 2020; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read the original:
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. - GlobeNewswire

Global Predictive Genetic Testing Market 2020: Type & Application, Innovation, Technology, Top Key Players, Regions & Forecast till 2025 -…

Global Predictive Genetic Testing market analysis forecast to 2025 is a specialized and in-depth study of the industry with a focus on the global market trend. The report aims to provide an overview of global Predictive Genetic Testing market with detailed market segmentation by solution, deployment type, application, vertical and geography. The global Predictive Genetic Testing market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

Adroit Market Research provides analysis and insights regarding on Predictive Genetic Testing market the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.

Adroit Market Research provides analysis and insights regarding on Predictive Genetic Testing market the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.

Top Leading Key Players are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Get sample copy of Predictive Genetic Testing Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/1276

The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The Predictive Genetic Testing market report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

In addition, the report categorizes Predictive Genetic Testing market according to type, application, related technology, end user, etc. to provide the data explored. It also includes comprehensive data related to specific financial and business terms, projected market growth, market strategy, etc. This market report offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the Global Predictive Genetic Testing Market.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

The research report on global Predictive Genetic Testing market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Predictive Genetic Testing market. This market study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

Key Highlights Questions of Predictive Genetic Testing Market:What will be the size of the global Predictive Genetic Testing market in 2025?Which product is expected to show the highest market growth?Which application is projected to gain a lions share of the global Predictive Genetic Testing market?Which region is foretold to create the most number of opportunities in the global Predictive Genetic Testing market?Will there be any changes in market competition during the forecast period?Which are the top players currently operating in the global Predictive Genetic Testing market?

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See the article here:
Global Predictive Genetic Testing Market 2020: Type & Application, Innovation, Technology, Top Key Players, Regions & Forecast till 2025 -...

Archives